LncRNA CDKN2B-AS1 C-Allele: A High-Risk Genetic Determinant in Cancer Susceptibility and Progression Impacting Immune Cell Modulation Dynamics with Therapeutic Implications

--Manuscript Draft--

Article Type:	Original Research Article
Keywords:	ANRIL; Immune Cells; Immune checkpoints; Palbociclib; EPC
Corresponding Author:	Nehman Makdissy Lebanese University LEBANON
First Author:	Nehman Makdissy
Order of Authors:	Nehman Makdissy
	Elisa Makdessi
	Samar El-Hamoui
	Fida El-Ayoubi
	Malak Naboulsi
	David Wehbe
	Noha Ibrahim
	Nadine Nasreddine

Abstract:	Examining LncRNA-driven cancer biology, our study represents the first comprehensive investigation of the LncRNA CDKN2B-AS1 across multiple cancer types, revealing its genetic basis for cancer susceptibility, and associations with thromboembolic risks and immunological dynamics. Stratification across hematological and non-hematological cancers revealed predominant prevalence rates of the CDKN2B-AS1 C-allele, notably higher in solid tumor malignancies, peaking at 86.8% in colorectal carcinoma (CRC). CRC-C-carriers exhibited worse outcomes, marked by reduced overall survival, increased venous-thromboembolism, elevated frequencies of thromboembolic-associated gene polymorphisms and BRAF mutations, and decreased MSI-H. Key tumor progression aspects in CRC-C-carriers included an inflammatory profile, angiogenesis, endothelial activity, decreases in tumor suppressor-CD146+ cells, shifts in tumor-infiltrating immune cells towards an immunosuppressive microenvironment, and marked elevation in tumor activity markers (Ki-67, CEA, CA 199, EGFR, VEGF-A, PD-1, and CTLA-4). Successful CDK4/6 inhibitor therapy with Palbociclib increased the progression-free survival median to 20 months, primarily by inhibiting cell proliferation. This underscores the multifaceted role of LncRNA CDKN2BAS1, presenting it not just as a genetic determinant but also as a potential prognostic biomarker in cancer dynamics, paving the way for targeted personalized interventions, representing promising advancements in cancer therapeutics.

Original Article

Title Page

Title:

LncRNA CDKN2B-AS1 C-Allele: A High-Risk Genetic Determinant in Cancer Susceptibility and Progression Impacting Immune Cell Modulation Dynamics with Therapeutic Implications

Authors' names:

Elisa Makdessi[1], Samar El-Hamoui[1,‡], Fida El-Ayoubi[1,‡], Malak Nabulsi[2], David Wehbe[2], Noha Ibrahim[1], Nadine Nasreddine[1], Nehman Makdissy[1,*]

Authors' affiliations:

1 Lebanese University, Faculty of Sciences III, Genomic Surveillance and Biotherapy GSBT Laboratory, Lebanon

2 Haykel Hospital, Lebanon

‡ These authors contributed equally to this work.

* To whom correspondence should be addressed: nehman.makdissy@ul.edu.lb

Corresponding author:

Prof. Nehman Makdissy; Lebanese University, Faculty of Sciences III, Ras-Maska, Lebanon; email: nehman.makdissy@ul.edu.lb

Keywords:

ANRIL; Immune Cells; Immune checkpoints; Palbociclib; EPC

Number of Figures:7

Number of Tables: 3

Number of Supporting Information: N/A

Abstract

Examining LncRNA-driven cancer biology, our study represents the first comprehensive investigation of the LncRNA CDKN2B-AS1 across multiple cancer types, revealing its genetic basis for cancer susceptibility, and associations with thromboembolic risks and immunological dynamics. Stratification across hematological and non-hematological cancers revealed predominant prevalence rates of the CDKN2B-AS1 C-allele, notably higher in solid tumor malignancies, peaking at 86.8% in colorectal carcinoma (CRC). CRC-C-carriers exhibited worse outcomes, marked by reduced overall survival, increased venous-thromboembolism, elevated frequencies of thromboembolic-associated gene polymorphisms and BRAF mutations, and decreased MSI-H. Key tumor progression aspects in CRC-Ccarriers included an inflammatory profile (reduced Th2 and increased Th1/Th17 cells), angiogenesis and endothelial activity (elevated CD14+, CD31+, CD144+, and VEGFR2+ cells), decreases in tumor suppressor-CD146^{+} cells (elevated tissue-adherent TA-EPCs lacking CD146), shifts in tumor-infiltrating immune cells towards an immunosuppressive microenvironment (M1-to-M2-like macrophage shift, increases in CD4+ and CD25+ cells and decreases in CD8+, CD56+, and CD11c+ cells), and marked elevation in tumor activity markers (Ki-67, CEA, CA 19-9, EGFR, VEGF-A, PD-1, and CTLA-4). Successful CDK4/6 inhibitor therapy with Palbociclib increased the progression-free survival median to 20 months, primarily by inhibiting cell proliferation. This underscores the multifaceted role of LncRNA CDKN2B-AS1, presenting it not just as a genetic determinant but also as a potential prognostic biomarker in cancer dynamics, paving the way for targeted personalized interventions, representing promising advancements in cancer therapeutics.

Abbreviations: : CDK, cyclin-dependent kinase; CDKN2B, cyclin-dependent kinase inhibitor 2B; CDKN2B-AS1, cyclin-dependent kinase inhibitor 2B anti-sense 1; CICs, circulating immune cells; CIICs, circulating infiltrated immune cells; CRC, colorectal cancer; EPC, endothelial progenitor cells; hPBMCs, human peripheral blood mononuclear cells; LncRNA, long non-coding RNA; MSI, microsatellite instability; MSS, microsatellite stability; NK, natural killer; PCR, polymerase chain reaction; VTE, venous

thromboembolism.

1. Introduction

Recent decades have witnessed an impactful shift in cancer biology, highlighting the pivotal involvement of long non-coding RNAs (lncRNAs) in tumor initiation, progression, and metastasis [1]. LncRNAs, a novel class of regulatory molecules, have been found to be dysregulated in a wide range of cancer types, often exhibiting aberrant expression patterns closely associated with clinical outcomes [2]. As their name suggests, lncRNAs do not directly translate into functional proteins; rather, they exert their influence by modulating the expression, stability, and localization of other genes through diverse mechanisms, including transcriptional regulation, post-transcriptional processing, and epigenetic modifications [3]. The complex nature of lncRNA-mediated gene regulation has positioned these non-coding RNAs as critical players in the complex networks that govern the hallmarks of cancer, such as uncontrolled cell proliferation, evasion of apoptosis, angiogenesis, and metastatic dissemination suggesting their immense potential as diagnostic, prognostic, and therapeutic biomarkers in oncology [4].

One genomic region that has garnered significant attention in the context of lncRNAs and cancer is the 9p21 locus [5]. This chromosomal region is known to harbor several tumor suppressor genes, including CDKN2A and CDKN2B, which play crucial roles in cell cycle regulation and tumor suppression [6]. Genetic variants and alterations within the 9p21 locus have been associated with a wide range of cancers, including leukemia, gliomas, ovarian, breast, and pancreatic cancers [7]. The lncRNA CDKN2B-AS1, also known as ANRIL, is one of the key players within the 9p21 locus. ANRIL plays a role in cancer development and progression [8], cell proliferation, apoptosis, inflammation, and extracellular matrix remodeling [9]. Elevated ANRIL levels are linked to lower survival rates and higher metastatic rates in CRC patients [10], and downregulation inhibits lymph angiogenesis and lymphatic metastasis [11], thus relating CDKN2B-AS1 to CRC progression [12] and being a risk locus [13]. Mechanistically, ANRIL

functions as a molecular scaffold, interacting with poly-comb repressive complexes to modulate the expression of neighboring tumor suppressor genes, CDKN2A/B. CDKN2B encodes for the protein p15Ink4b that leads to cell cycle arrest by the inhibition of CDK4/6, thus impacting tumor cell proliferation. The C/G polymorphism within the ANRIL gene can contribute to the development and progression of various cancers. In fact, CDKN2B-AS1 carrying the G-allele promotes CDKN2B, while C-allele inhibits

CDKN2B, leading to a converse effect of cell cycle progression [14,15]. Carriers of the C-allele have a higher risk of developing breast cancer and a lower survival rate in esophageal squamous cell carcinoma [16,17].

Primary complications in active or post-operative stages of cancer relate to the coagulation system, particularly is the thromboembolism. CDKN2B-AS1(C/G) polymorphisms' association with increased risk of vascular diseases has been studied extensively [18–21], suggesting involvement in cancer-related thromboembolism [22]. It is crucial to target the hemostatic system by identifying thromboembolic risk biomarkers and as a target for anticancer therapy. Leading to activation of the coagulation system [23]and tumor progression [24], cancer cells activate vascular cells, release procoagulants, control fibrinolysis, and produce inflammatory and angiogenic cytokines, contributing to prothrombotic disorder of the vascular wall [25]. Cancer patients, especially those given systemic chemotherapy, are at much higher risk of thromboembolism due to abnormal blood clotting mechanisms [26].

In fact, despite the therapeutic progresses for effective anticancer therapy including chemotherapy, targeted therapies, immunotherapy, cell-based therapy, and sometimes radiation therapy, several treatments remain ineffective. Angiogenesis, inflammatory and highly proliferative tumor with certain genetic predisposition and genomic stability, might present challenges for certain types of treatments. Therefore, beyond the mutational signatures and molecular events that occur in cancers, the tumor

microenvironment is central in understanding immunosurveillance and immunoediting in cancers [27] , which describes interactions between the immune system and the tumor that allow cancer cells to evade immune surveillance, leading to tumor growth, chronic inflammation, and metastasis. The significance of how the inflammatory environment determines the immunological pathogenesis of cancer has been demonstrated by research on the activation patterns of immune cells and stromal cells [28]. Cancer prognosis is linked to immunological subsets, including central immune effector T cells ($CD8^+$, $CD25^+$), NK cells, and macrophages [28,29]. The production of Tregs and immunosuppressive factors like PD-1 [30], which puts $CD8^+$ T-cells in a state of anergy [31,32], can hinder successful therapy, leading to the development of checkpoint blockade medications by preventing T-cell exhaustion or depleting Tregs [30]. Understanding the antitumor immune response and combining various strategies may enable effective immunotherapy for cancer treatment [30]. For instance, a chemo-immunotherapy trial stimulated human peripheral blood mononuclear cells

(PBMCs) with colon cancer cells to produce cytotoxic T-cell lines specific for the disease [33]. Most therapies, including chemotherapy and biotherapy, have immunomodulatory effects that trigger immunogenic cell death and prevent immunosuppression.

Other than the genetic predisposition which may affect the immune system, circulating immune cells (CICs) and endothelial progenitor cells (EPCs) cells, and circulating infiltrated immune cells (CIICs), are promising for cancer therapy. CICs, such as $CD4^+$ and $CD8^+$ cells which are subsets of immune PBMCs provide insights into systemic immune responses and potential biomarkers for disease monitoring and treatment response. EPCs, subsets of bone marrow-derived stem cells implicated [34], in tumor angiogenesis and vascular remodeling, shed light on the tumor's vascular network and metastatic potential, guiding anti-angiogenic therapies and prognostic evaluations. CIICs, comprising diverse immune cell subsets recruited to the tumor site, unveil mechanisms of immune evasion and inform

immunotherapy strategies, aiding in patient stratification and treatment monitoring. Integrating assessments of these circulating entities and their relations with the LncRNA CDKN2B-AS1 variants, enables a complete understanding of cancer dynamics and facilitates the development of targeted interventions for improved patient outcomes.

While the dysregulation of CDKN2B-AS1 (ANRIL) has been reported in some cancer types, however CDKN2B-AS1 C/G prevalence across multiple types of cancer wasn't studied previously. The majority of existing studies didn't provide a holistic understanding of its significance in the context of diverse cancer biology. This knowledge gap limits our ability to establish ANRIL and its genetic variants as a robust prognostic and predictive biomarker, as well as to explore its potential as a therapeutic target in cancer management. At our knowledges, no previous study had reported in cancer the role of a potential LncRNA with CICs, EPCs, and CIICs, in one single study.

Therefore, the objective of this study is to investigate the LncRNA CDKN2B-AS1 variants in cancer susceptibility, thromboembolic risk and immunological dynamics as predictive and prognostic biomarkers. This study is to also provide a deeper understanding of lncRNA-driven cancer biology, evaluating the immune-inflammatory identity, the angiogenic factors and immune checkpoints, to guide personalized treatment strategies for cancer patients. Addressing this gap through a comprehensive investigation of CDKN2B-AS1 in diverse cancer contexts would significantly advance the field of cancer research and inform the development of more effective, personalized therapies, ultimately improving patient outcomes.

2. Material and Methods

2.1 Study design

The study involves a diverse group of 882 eligible outpatients aged 21-89 years, both males and females, diagnosed with various types of cancers, both hematological and non-hematological, as per the World Health Organization (WHO) cancer classification. Specifically, the study focuses on CRC, and the patients were diagnosed through colonoscopy and confirmed by evaluating the expression of specific genes and protein biomarkers. Aimed to cover a comprehensive understanding of the circulatory system and its crucial role in cancer, our investigations centered on the analysis of genes and proteins within the circulatory system relevant to thrombosis, thromboembolism, coagulation, etc. Concurrently, we conducted a thorough vascular assessment based on electrocardiography, echocardiography, and serum biomarker analysis to appraise vascular structure, function, and overall vascular health. The main assays utilized for screening and assessing biomarkers include immunohistochemistry, immunofluorescence microscopy, and PCR. Additionally, immunological markers were assessed using techniques such as flow cytometry, ELISA, and immune cell functional assays. Through the integration of these assessments, distinct patient subgroups were identified based on immunological, vascular, and cancer parameters. Selected CRC patients were further categorized into subgroups based on the cancer staging classified according to the AJCC TNM staging system, with specific exclusion criteria employed to ensure data integrity. These criteria ensure a focused examination of the targeted population and their background profiles concerning CRC, immunological factors, immunomodulation, vascular health, and related diseases. On the other hand, the staging of hematological cancers used the Ann Arbor staging system for

Hodgkin lymphoma, the Lugano classification for non-Hodgkin lymphoma, and the French-AmericanBritish (FAB) classification for Leukemias.

Patients have not received any form of therapy (radiotherapy, chemotherapy, immunotherapy, or cellbased therapy) at the time of diagnosis. The study outlines specific exclusion criteria to ensure the integrity of the data: inflammatory bowel diseases, cardiovascular diseases, coronary artery diseases, confirmed treated or untreated autoimmune, metabolic, diabetes, or neurological diseases. Additionally, individuals with evidence of cardiac, renal, bone, or cerebral damage, infections, myositis, familial polyposis, alcohol or smoking habits, colon-affecting food allergies, body mass index >30, significant weight loss within the last 2 years, history of abdominal surgeries, or pregnancy are also excluded.

The study was registered as a clinical study on clinicaltrials.gov with the identifier NCT06065592, titled "Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms (CAT_PB)", and conducted at the Haykel Hospital and the duration of the study was sixty months. The principal investigators enrolled patients and conducted follow-ups with all patients and collected comprehensive data on laboratory results, treatments, and outcomes from clinical records.

2.2 Serological and Blood Analyses

Blood samples were collected from both suspected subjects and selected patients, following standard procedures and laboratory operating protocols. A comprehensive list of assessments was performed on the blood samples, including measurements of complete blood count (CBC) or serology tests for albumin, globulin, total bilirubin, direct bilirubin, total proteins, creatinine, estimated glomerular filtration rate (eGFR), urea, uric acid, sodium, potassium, chloride, calcium, vitamin B12, vitamin D, blood sugar, hemoglobin A1c (HbA1c), total cholesterol (T-Chol), high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides (TG), prothrombin time (PT), activated partial thromboplastin time

(aPTT), D-dimer, fibrinogen, troponin, antithrombin III (ATIII), protein C, protein S, serum complement C3 and C4, double-stranded DNA (dsDNA), antinuclear antibodies (ANA) and ANA profile, antineutrophil cytoplasmic antibodies (ANCA) and ANCA profile, lactate dehydrogenase (LDH), Creactive protein (CRP), interleukin-6 (IL-6), iron, ferritin, homocysteine, creatine phosphokinase (CPK), complement C3, complement C4, antithrombin III (ATIII), lupus anticoagulant, antiphospholipid antibodies, anti-cardiolipin antibodies, alanine aminotransferase (ALT or SGPT), aspartate aminotransferase (AST or SGOT), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), lipase, amylase, thyroid-stimulating hormone (TSH), hemoglobin, hematocrit, red blood cells (RBC), white blood cells (WBC), platelets, neutrophils, lymphocytes, monocytes, eosinophils, basophils, and erythrocyte sedimentation rate (ESR). For PCR assays, whole blood samples collected in EDTA tubes were utilized.

2.3 Human PBMCs Preparation

Twenty ml of fresh peripheral venous blood were collected into EDTA tubes. The blood was then diluted 1:1 with phosphate-buffered saline (PBS) and carefully layered over Ficoll-Paque PLUS, following which centrifugation (30 min, 400xg) at room temperature. The hPBMC layer was pooled and transferred into a 15-ml falcon tube. The sample was further diluted 1:1 with PBS and centrifuged again (5 min, 250xg) at room temperature. The resulting pellet was resuspended with 5 ml of PBS and subjected to centrifugation at 250xg for 5 min. The cell pellet was finally resuspended in 2 ml of PBS. Manual and flow cytometrybased cell counting methods were employed.

2.4 CDKN2B-AS1 and Thromboembolic-associated Genes Genotyping

For genotyping of CDKN2B-AS1, all individuals were genotyped for the chr9p21.3 rs1333049 polymorphism (C/G, Transversion Substitution) using the TaqMan SNP allelic discrimination

genotyping assay (Applied Biosystems, Thermo Fisher Scientific, CA, USA; assay identification C__1754666_10,

Cat# 4351379). A total of 20 ng of purified DNA were amplified in a final volume of 10 μL per well in 384 well plates with a PCR cycling protocol of initial denaturation at 95°C for 10 min, followed by 40 cycles at 92°C for 15 sec and 60°C for 1 min. Post PCR allelic discrimination was carried out by measuring allele-specific fluorescence on an ABI prism® 7500 Sequence Detection System (Applied Biosystems) using the ABI Prism SDS software version 2.1 (ABI). Genotyping was successful in 97% of rs1333049 polymorphism. TaqMan SNP Genotyping Assays required only three reaction components for PCR: purified genomic DNA, the assay solution, and TaqMan Genotyping Master Mix. Internal probes were:

VIC™ (5'), FAM (5'), MGB (Minor Groove Binder) (3'), where labels (dye) were VIC (probe 1, to detect the allele C) and FAM (probe 2, to detect the allele G); The well contains a known template to generate a specific genotype call for an assay, specifying positive controls for VIC/VIC, VIC/FAM, or FAM/FAM.

FAM™ and VIC® dye fluorescent values are normalized by the ROX passive reference dye. The context sequence [VIC/FAM] is:

CATACTAACCATATGATCAACAGTT[C/G]AAAAGCAGCCACTCGCAGAGGTAAG.

For genotyping of thrombophilic-Related Gene Polymorphisms (TRGP, genes and polymorphisms associated with blood clot formation and thrombotic events, such as deep vein thrombosis, pulmonary embolism, and arterial thrombosis), and other Vascular-Related Gene Polymorphisms (VRGP, genes and polymorphisms involved in lipid metabolism, and inflammation), stripassay assessment by multiplex PCR and reverse-hybridization were applied as previously described [35], utilizing Viennalab

Biotechnology and SNP Biotechnology. In total, 16 polymorphisms for 12 genes were assessed: blood coagulation Factor

II Prothrombin (G20210A), Factor V [Leiden (1691G>A, R506Q), R2 (4070A>G, H1299R), Cambridge (1091G>C, R306T), and 1702 (5189A>G, Y1702C)], Factor XIII (103G>T, Val34Leu), MTHFR [(677C>T, A222V) and (1298A>C, E429A)], MTR (2756A>G, D919G), MTRR (66A>G, I22M), BetaFibrinogen (455G>A), HPA-1 Platelet Glycoprotein IIIa (L33P (a/b)), PAI-1 (4G/5G), ACE (I/D, Ins/Del), Apo B (R3500Q), and Apo E (E2/E3/E4).

2.5. KRAS and BRAF Mutation Assessment

Mutation analyses for KRAS and BRAF were performed in formaldehyde fixed-paraffin embedded (FFPE) tissues. Genomic DNA was extracted using the QIAamp DNA FFPE tissue Kit following the manufacturer's protocol (Qiagen, USA). DNA content was quantified using NanoDrop ND-1000 (Nanodrop, USA), and the identification of KRAS and BRAF mutations was based respectively on KRAS XL and BRAF 600/601 StripAssay PCR and reverse-hybridization (Viennalab, Austria). The detection of somatic mutations in and near codons 12 and 13 in Exon 2, codons 59 and 61 in Exon 3, and codons 117 and 146 in Exon 4 in the human KRAS gene, and codons 600 and 601 were evaluated.

2.6. MSI status and Other Biomarkers Analysis

Microsatellite status was determined by Immunohistochemical (IHC) assessing on tumor biopsy the mismatch repair (MMR) proteins, including MLH1, MSH2, MSH6, and PMS2; MSI phenotype tumors were defined as presenting with the loss of one or more MMR proteins' expression. The absence of nuclear staining in neoplastic cells defined MMR protein loss. In addition, tumor biopsies were labelled

with human conjugated antibodies directed against CEA, CA 19-9, EGFR, VEGF-A, PD-1, CTLA-4, and Ki67,

and analyzed by IHC.

2.7. Immunohistochemical Profiling of Tumor Markers and Immune Cell Infiltration

IHC was utilized to identify tumor markers, tumor-infiltrating immune cells (TIICs), and other pertinent markers in formalin-fixed paraffin-embedded tissue samples. Expert pathologists reviewed hematoxylineosin-stained slides to confirm diagnoses. Automated immunostainers were employed to ensure consistency during the staining process, incorporating appropriate positive and negative controls. Markers investigated include, but are not limited to: immune cell markers such as CD3, CD4, CD8, CD5DIN, CD7, CD15, CD20, CD23, CD30, CD34, CD38, CD43, CD45, CD79a, and CD138; proliferation markers KI67 and Cyclin D1; oncogenes/tumor suppressor genes p53, b-2 microglobulin, bcl 2, bcl 6, Myeloperoxidase, Muramidase, PDL1, and HER2; hormone receptors Estrogen and Progesterone; and other pertinent markers TPS-A, CD10, CD17, E-cadherin, GATA3, and PAX5.

2.8. Immunophenotyping of CICs, EPCs, immune checkpoints, Th cells, and cytokines production

Flow cytometry was used to assess the immunophenotyping of cell surface markers expressed by CICs and EPCs, as well as viability and apoptotic index using 7AAD/Annexin V/PI staining, and immune checkpoint expression targeting CD152 (CTLA-4) and CD279 (PD-1). The analyses were performed as described previously [36,37]. Immunophenotyping was carried out using human conjugated Abs (Vioblue, FITC, APC, PerCP, PE, etc.) and isotype control Abs. $1x10^5$ cells were stained and analyzed by flow cytometry. Isotype and automated compensation were adjusted to minimize false positive fluorescence and spectral overlap of fluorochromes, respectively. Data based on 20,000 events were acquired from each sample in a user-defined gate and analyzed.

For Th1, Th2, and Th17 immunophenotyping assays, cells were fixed, permeabilized and stained using a mixture of CD4 PerCP-CY5.5, IFN-γ-FITC, IL-4-APC, and IL-17A-PE Abs according to the manufacturer's instructions (Human Th1/Th2/Th17 Phenotyping kit, BD Biosciences). Analyses were realized by flow cytometry. The cytokines levels were assessed using the MACSPlex cytokine 12 kit (Miltenyi) following the manufacturer instructions.

For EPCs immunophenotyping, we utilized a sequential gating strategy to distinguish three distinct phenotypes. Initially, we gated on the CD45 marker to select the CD45-negative population, primarily composed of non-hematopoietic cells. Then, within this CD45-negative population, we further gated on the CD34 marker to isolate CD34-positive cells. Following this, we gated on the KDR (VEGFR-2)positive population, representing cells with endothelial lineage potential. Within the KDR-positive population, we then gated on the CD31 (PECAM-1)-positive cells, refining our selection to endothelial cells. Further gating based on CD144 and CD146 enabled the identification of three distinct phenotypes: Phenotype "A" ($CD45^-/CD34^+/KDR^+/CD31^+/CXCR4^+/CD144^{-/}CD146^-$), Phenotype "B" ($CD45^-/CD34^+/KDR^+/CD31^+/CXCR4^+/CD144^+CD146^-$), and Phenotype "C" ($CD45^-/CD34^+/KDR^+/CD31^+/CXCR4^+/CD144^+/CD146^+$).

2.9. Treatments

Chemotherapy and Targeted therapies were applied. Chemotherapy regimen consisted of CAPOX (capecitabine and oxaliplatin), and operates in 3-week cycles, with 8 cycles in total. The chemotherapy regimen consisted of a cycle of CAPOX (130 mg/m^2 of intravenous oxaliplatin on Day 1 of each 21-day cycle, plus 1,000 mg/m^2 of oral capecitabine twice daily given for 14 days followed by a 7-day rest period, repeated at 3-week intervals). Targeted Therapy consisted of using Palbociclib (PAL) 125 mg

orally once a day for 21 consecutive days followed by 7 days off. Patients were administered either CAPOX alone or a combination of CAPOX and PAL (CALPOX as first-line treatment, and PAL as second-line treatment).

2.10. Tumor Regression and Clinical Response Evaluations in Treatments

Tumor regression after 2 cycles of treatment was assessed using CT scans for evaluation of either progressive or stable disease. The initial assessment included medical history, clinical examination, full laboratory analysis, and metastatic evaluation using chest CT, enhanced CT or MRI of the abdomen and pelvis, colonoscopy, and tumor biopsy. The clinical responses were assessed following the Response Evaluation Criteria in Solid Tumors version 1.1 guideline (RECIST version 1.1). Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.02 (CTCAE version 4.02).

2.11. Statistical analysis

Kaplan-Meier analysis was utilized to assess survival probabilities, and alongside this, Log-rank (Mantel-Cox) test, Logrank test for trend, Gehan-Breslow-Wilcoxon test, Median survival, Hazard Ratio (MantelHaenszel), and Hazard Ratio (logrank) were conducted to comprehensively evaluate outcomes differences and trends in outcomes. For a parameter to be reported, at least four tests must be significant, ensuring robustness in the findings regarding the association between the studied parameter and outcomes in our study population. Additionally, Cox proportional hazards regression analysis was employed to assess the association between predictor variables and time-to-event outcomes, particularly focusing on the risk factors associated with mortality. Consistently, a significance level of $\alpha = 0.05$ and

two-tailed P values ensured vigorous statistical evaluation, contributing to an in-depth understanding of LncRNA CDKN2B-AS1 variants' impact on patients.

3. Results

3.1. Genetic Analysis of LncRNA CDKN2B-AS1 Variants in Cancer Susceptibility: Highlighting High Prevalence of Risk Allele "C" in Solid Cancers

We screened 1,743 unrelated outpatients, of which 882 met the study criteria, exhibiting a male-to-female ratio (M/F) of 0.66 and a mean age of 49.5 ± 0.74 years, clinically suspected of having cancers (Table IA).

Among them, 380 were diagnosed as cancer-free (CF group), while 502 were classified as cancer-positive (CP group).

Initially, LncRNA CDKN2B-AS1 genotyping for the alleles (C) and (G) was conducted in CF and CP groups across 23 types of cancers (Table IB). CP patients exhibited a notably high frequency of the C-allele (0.76, denoted as C-carriers) and a lower frequency of the G-allele (0.24, denoted as non-C-carriers). The expression of the C-allele was significantly predominant in CP compared to CF (OR: 9.04, P<.0001).

Subsequent stratification into hematological and non-hematological cancers revealed distinct prevalence rates, highlighting the potential role of the C-allele in cancer susceptibility, particularly in solid tumors (0.79; OR: 10.8, P<.0001) compared to hematological malignancies (0.52; OR: 3.05, P<.0005). Notably, in hematological cancers, the C-allele exhibited significantly higher occurrence in lymphocytic malignancies (0.61; OR: 4.37, P<.0001), while in non-hematological cancers, its highest prevalence was observed in gastrointestinal carcinomas, notably colorectal carcinoma (CRC) (0.87; OR: 18.6, P<.0001), followed by lung cancers (0.80; OR: 11.4, P<.0001), and ovarian cancers (0.79; OR: 11.1, P<.0001).

Given its prevalent presence, especially in solid tumors, the C allele was designated the "Risk allele" for its association with cancer susceptibility across various types of cancers.

Table I: Baseline Parameters of the Cohort and Prevalence of the CDKN2B-AS1 'C' Allele in Diverse Cancer Types

A - Baseline characteristics	Total	**Cancer-Free** [1]		**Cancer-Positive** [2]			
Total Population – *n*	882	380		502			
Age, years (Mean ± SEM)	49.5 ± 0.74	46.8 ± 0.94		54.7 ± 0.82			
Gender (male-to-female ratio (M/F))	(0.66)	(0.47)		(0.81)			
Race, white (%)	(100%)	(100%)		(100%)			
B - Occurrence of CDKN2B-AS1 "C" allele [3]	Total – *n*	**non-C-carriers**		**C-carriers**		**OR**	***P***
Total Population – *n (%)*	882	401	(45.5)	481	(54.5)		
Cancer-Free	380	281	(73.9)	99	(26.1)		
Cancer-Positive	502	120	(23.9)	382	(76.1)	9.04	<.0001
Hematological Cancer [4]	56	27	(48.2)	29	(51.8)	3.05	<.0005
Lymphocytic Cancer	33	13	(39.4)	20	(60.6)	4.37	<.0001
Myeloid Cancer	23	14	(60.9)	9	(39.1)	1.82	NS
Non-Hematological Cancer	446	93	(20.9)	353	(79.1)	10.8	<.0001
Gastrointestinal (GI) Cancers: Lower GI - Colorectal Carcinomas [5]	219	29	(13.2)	190	(86.8)	18.6	<.0001
Middle GI - Hepatobiliary Carcinomas [6]	23	5	(21.7)	18	(78.3)	10.3	<.0001
Upper GI - Gastric, Pancreatic Carcinoma [7]	16	7	(43.8)	9	(56.2)	3.65	<.05
Genitourinary Cancers:							
Ovarian & Other [8] Gynecologic Carcinomas	49	10	(20.4)	39	(79.6)	11.1	<.0001
Prostate Carcinoma	27	9	(33.3)	18	(66.7)	5.68	<.0001
Bladder Carcinoma	23	10	(43.5)	13	(56.5)	3.69	<.005
Other Solid Tumor Carcinomas:							
Lung Carcinomas [9]	35	7	(20.0)	28	(80.0)	11.4	<.0001
Breast Carcinoma	51	15	(29.4)	36	(70.6)	6.81	<.0001

Brain Carcinoma (including Glioblastoma)	3	1	(33.3)	2	(66.7)	5.68	NS

Table I Footnote: *(1) Cancer-Free subjects initially suspected to have cancer for whom diagnostic tests showed no evidence of cancer; (2) Cancer-Positive subjects initially suspected to have cancer who were diagnosed with either hematological or solid tumors; (3) At the time of diagnosis; (4) Included myeloid (Multiple Myeloma, Myelodysplastic Syndrome, Leukemia) and lymphocytic (T-cell lymphoma, B-cell lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma) cancers; (5) Included cancers of both the colon and rectum; (6) Included liver carcinomas and cholangiocarcinoma; (7) Included gastric adenocarcinoma and pancreatic ductal adenocarcinoma; (8) Included endometrial, endocervical, and uterine carcinomas; (9) Included NSCLC (NonSmall Cell Lung Carcinoma) and non-NSCLC. OR, Odd Ratio; P<.05, P<.01, P<.001, P<.0005, P<.0001: Cancer vs. Control.*

3.2. CRC Susceptibility, Mortality, and Thromboembolic Risk: Stratification by C-carrier Status To explore the impact of the risk allele on CRC susceptibility, a cohort of 448 subjects was examined. Among them, 229 individuals formed the control group, while 219 subjects constituted the CRC group. Within the CRC group, patients were further classified based on the AJCC TNM staging system, covering stages 0-IV, representing the early (Stages 0 and I, CRC-ES-group, characterized by localized tumors), mid

(Stage II, CRC-MS-group, indicating deeper infiltration) and advanced stages of CRC (Stages III and IV, CRC-AS-group, denoting distant CRC). Notably, all participants were non-hospitalized at the time of diagnosis and had not undergone any prior lines of therapy.

Data from the CRC group revealed significant insights (Table IIA): (1) the primary tumor was predominantly situated on the left side of the colon (59.8%), although 32.9% of patients exhibited rightsided adenocarcinomas; (2) surgical interventions predominantly resulted in complete resection (60.3%), with 26.0% of patients undergoing partial resection; (3) the majority of CRC patients demonstrated a predominant tumor grade of moderately differentiated histology (79.0%), while a

minority presented with poorly differentiated (12.8%) or well-differentiated (8.2%) histology; (4) over the 60-month study duration, aside from hospitalization related to therapy, 14.6% of patients required hospitalization, with an average length of stay (LOS) of 9.1 days, and only 1.8% were admitted to the intensive care unit (ICU); (5) the incidence of mortality within the CRC group was 10.9%.

Significant differences were observed among the groups for the primary clinical endpoint of mortality (Table IIB1). Mortality rates were notably elevated in the CRC-MS (11.7%; OR: 30.2, P<.0001) and CRCAS (20.3%; OR: 58.0, P<.0001) groups compared to the control (0.44%), indicating an increased risk of mortality with advanced staging of CRC. Among C-carriers, mortality rates were significantly elevated also in the CRC-MS (11.7%; OR: 17.7, P<.0005) and CRC-AS (18.9%; OR: 31.7, P<.0001) groups compared to controls (0.0%). Conversely, non-C-carriers showed negligible mortality rates across all groups. These findings underscore the impact of the CDKN2B-AS1 C-allele on mortality rates in CRC patients, with implications for risk stratification and personalized treatment approaches.

In light of the increased risk of venous thromboembolism (VTE), including Pulmonary Embolism (PE) and

Deep Vein Thrombosis (DVT), among CRC patients, monitoring for thromboembolic events is principal. Given the multifactorial nature of VTE, including genetic influences, we examined the association between

CDKN2B-AS1 polymorphism, specifically the C-allele, and VTE susceptibility in CRC patients (Table IIB2). Significantly elevated VTE rates were observed in CRC patients with mid-stage (23.4%; OR: 4.25, P<.0005) and advanced stage (29.7%; OR: 5.90, P<.0001) disease compared to the control group (6.99%).

Moreover, C-carriers exhibited significantly heightened VTE rates in both CRC-MS (20.8%; OR: 2.67, P<.05) and CRC-AS (27.0%; OR: 3.83, P<.005) groups relative to controls (2.62%). Conversely, noncarriers showed lower VTE rates across all groups. Elevated levels of D-dimer and fibrinogen, along

with shortened aPTT, were notably higher in CRC-AS patients (39.2%, 32.4%, and 29.7%) compared to the control group (5.2%, 8.7%, and 6.1%), respectively, supporting heightened coagulation activity.

When comparing CRC staging to the control for overall survival (OS) and the incidence of VTE, KaplanMeier curves for survival revealed significant differences associated with C-carriers, rather than non-Ccarriers (Fig.1A,B). Kaplan–Meier analyses demonstrated notable decreases in OS and a higher incidence of VTE, particularly evident in CRC-AS. Across the total population, there were significant decreases in

OS (Log-rank=61.76, P<.0001), with more pronounced effects observed in patients who developed VTE (Log-rank=18.35, P<.0001), accompanied by a notably higher incidence of VTE (Log-rank=61.29, P<.0001). Among C-carriers, Kaplan–Meier analysis showed significant decreases in OS for the entire population (Log-rank=28.79, P<.0001) and patients who developed VTE (Log-rank=12.99, P<.005), coupled with an elevated incidence of VTE (Log-rank=19.63, P<.001).

Regarding the median overall survival time (mOS), a 60-month analysis revealed that for CRC patients, mOS ranged from 44 to 54 months, while for those with VTE, it varied from 36 to 49 months—contrasting with control values (54.5-60 and 51.5-53.5 months, respectively). Remarkably, the most pronounced differences in mOS emerged within CRC-AS C-carriers, dropping to 44 months—markedly lower than the 54 months noted in non-C-carriers. These differences were further accentuated among CRC-VTE patients, where mOS declined to 36 months in C-carriers, contrasting to 49 months in non-C-carriers.

These findings highlight the pivotal role of C-carrier status in shaping survival outcomes and increased risk of VTE. Understanding these relationships may contribute to improved risk assessment and management

strategies for VTE in CRC patients.

Table II: Baseline Characteristics and Clinical Endpoints of the Colorectal Cancer Cohort

A - BASELINE CHARACTERISTICS	**Control**	**CRC**
COHORT – *n*	229	219
Study Duration (*months*)	-	60
Age, years (Mean ± SEM)	52.2 ± 1.01	57.9 ± 0.98
Gender (male-to-female ratio)	0.92	1.31
Race, white	229	219
AJCC TNM STAGING [1] **–** *n (%)*	-	
0		4 (1.8%)
I	-	64 (29.2%)
II	-	77 (35.2%)
III	-	61 (27.9%)
IV	-	13 (5.9%)
LOCATION OF PRIMARY TUMOR [1] **–** *n (%)*	-	
Left side of the colon, including rectum		131 (59.8%)
Right side of the colon, including cecum	-	72 (32.9%)
Transverse	-	16 (7.3%)
PRIMARY TUMOR REMOVED – *n (%)*	-	
Completely resected (R0) [2]		132 (60.3%)
Partially resected	-	57 (26.0%)
TUMOR GRADE – *n (%)*	-	
Well differentiated histology		18 (8.2%)
Moderately differentiated histology	-	173 (79.0%)
Poorly differentiated histology	-	28 (12.8%)
HOSPITALIZATION OCCURRENCE	11 (4.8%)	32 (14.6%)
ICU admission **–** *n (%)* [3]	2 (0.87%)	4 (1.8%)

Length of stay (LOS) in-hospital, days (Mean ± SEM)	4.1 ± 0.9	9.1 ± 1.2
MORTALITY – *n (%)*	1 (0.44%)	24 (10.9%)
In-hospital mortality	1 (0.44%)	15 (6.8%)
In-ICU mortality	1 (0.44%)	3 (1.4%)

[Table II content continues...]

B - CLINICAL ENDPOINTS		ANOVA (*P*)	**Control**	**CRC-ES**	**CRC-MS**	**CRC-AS**
n Total			229	68	77	74
Age of total patients (yrs., Mean ± SEM)		<.0001	52.2 ± 1.01	53.7 ± 0.92	59.1 ± 0.87	60.9 ± 1.21
B.1. Primary Clinical Endpoint – MORTALITY						
Total Population	MORTALITY – *n (%)* [4]	<.0001	1 (0.44%)	0 (0.00%)	9 (11.7%)	15 (20.3%)
	SURVIVAL – *n*	<.0001	228	68	68	59
	OR			1.67	30.2	58.0
	P			NS	<.0001	<.0001
C-carriers	MORTALITY – *n (%)* [4]	<.0001	0 (0.00%)	0 (0.00%)	9 (11.7%)	14 (18.9%)
	SURVIVAL – *n*	<.0001	60	58	61	53
	OR			1.03	17.7	31.7
	P			NS	<.0005	<.0001
non-C-carriers	MORTALITY – *n (%)* [4]	NS	1 (0.44%)	0 (0.00%)	0 (0.00%)	1 (1.35%)
	SURVIVAL – *n*	<.01	168	10	7	6
	OR			8.4	12.0	28.0
	P			NS	NS	NS
B.2. Secondary Clinical Endpoint - VENOUS THROMBOEMBOLISM (VTE)						
Total Population	VTE – *n (%)* [4]	<.0001	16 (6.99%)	5 (7.35%)	18 (23.4%)	22 (29.7%)

	Non-VTE – *n*	<.05	213	63	59	52
	OR			1.11	4.25	5.90
	P			NS	<.0005	<.0001
C-carriers	VTE – *n (%)* [4]	<.0001	6 (2.62%)	4 (5.88%)	16 (20.8%)	20 (27.0%)
	Non-VTE – *n*	<.0001	54	54	54	47
	OR			0.66	2.67	3.83
	P			NS	<.05	<.005
non-C-carriers	VTE – *n (%)* [4]	<.0001	10 (4.37%)	1 (1.47%)	2 (2.60%)	2 (2.70%)
	Non-VTE – *n*	<.0001	159	9	5	5
	OR			1.77	6.36	6.36
	P			NS	NS	NS
Coagulation parameters						
High D-dimer (> 1000 ng/mL) – *n (%)* [4]		<.001	12 (5.2%)	13 (19.1%)	15 (19.5%)	29 (39.2%)
High Fibrinogen (> 700 mg/dL) – *n (%)* [4]		<.001	20 (8.7%)	9 (13.2%)	16 (20.8%)	24 (32.4%)
Shortened aPTT (< 20sec) – *n (%)* [4]		<.005	14 (6.1%)	8 (11.8%)	23 (29.9%)	22 (29.7%)

Table II Footnote: *[1] At the time of diagnosis; [2] Mostly for early-stage CRC 54.6% (Stages 0 to II) and only 5.4% (stage III); [3] Admission to ICU in cases of CRC-related complications in the CRC group, or colon problems in the control group; [4] Percentage relative to total number of patients per group; [5] PE and DVT, two main clinical manifestations collectively termed VTE. VTE occurrences during the study period were recorded, excluding patients with lower limb DVT or PE prior to the study. Other events counted as VTE included splenic, portal, superior mesenteric, and renal vein thrombosis. The overall VTE incidence, encompassing DVT and/or PE, was determined by: (i) Doppler-diagnosed DVT, indicated by elevated Ddimer/fibrinogen levels and shortened aPTT, combined with clinical symptoms (of swelling and pain of the lower limbs, tenderness behind the lower leg and/or medial thigh), and lower limb ultrasound; (ii) PE diagnosed by CTPA, along with relevant clinical signs (such as dyspnea and shortness of breath) and coagulability tests like plasma D-dimer. Odds Ratio (OR)*

and P-value: CRC-ES/MS/AS versus Control; ANOVA: analysis between the 4 groups. Abbreviations: LOS, length of stay; d., days; Yrs., years; PE, Pulmonary embolism; DVT, deep vein thrombosis; VTE, venous thromboembolism; CTPA, CT pulmonary

arteriography.





D

CDKN2B-AS1 Risk Allele	Total Population		VTE Population	
	OR	**P**	**OR**	**P**
CRC-ES vs. Control	16.30	<.0001	6.67	NS
CRC-MS vs. Control	28.16	<.0001	13.33	<.005
CRC-AS vs. Control	26.96	<.0001	12.22	<.005



<u>Fig.1 Legend</u>: CDKN2B-AS1 Genotyping and Kaplan-Meier Analysis in CRC Patients and CRC-VTE Patients. *DNAs were extracted from peripheral blood and transcribed, then amplified by PCR as described in Methods for screening of CDKN2BAS1 C-risk and G-protective alleles. Kaplan-Meier analysis of Overall Survival (A) and VTE incidence (B) in CRC cohort by*

*C-Carrier status. Results are expressed as the duration of patients' survival relative to the study period, presented as a percentage. (C) Genotyping in the total population, relative to CRC staging and CRC-associated VTE. Results are expressed as the percentage of subjects or patients with the indicated genotype within each respective group. (D) Significance variations of the risk allele (CC genotype) in correlation with CRC staging in both the total and VTE populations. (E) Allele Frequencies of Thromboembolism and Vascular-Related Gene Polymorphisms in C-carriers with CRC-AS. Risk alleles are indicated below each respective gene. Allele frequencies of the variants are expressed as percentages*P<.05; **P<.005; ***P<.001: C-carrier*

versus non-C-carrier. ES, Early Stage; MS, Mid Stage; AS, Advanced Stage; OR, Odd Ratio.

3.3. CDKN2B-AS1 Genotyping and Thromboembolic-Associated Gene Polymorphisms in CRC

The genotyping of CDKN2B-AS1 was assessed (Fig.1C). In contrast to controls, where G-carriers and GG genotype were predominant, CRC patients revealed a predominance of C-carriers, particularly with the CC genotype (60.7% prevalence). Remarkably, the CC genotype was significantly prevalent across all stages of CRC, showing consistent frequencies in CRC-ES, CRC-MS, and CRC-AS [73.5%, 75.3%, and 75.7% respectively (OR: 16.3, 28.2, and 27.0, P<.0001)]. Furthermore, among CRC patients who developed VTE (CRC-VTE), the incidence of the C-allele rose to higher levels, with a notable predominance of the CC genotype (Fig.1D) in CRC-ES, CRC-MS, and CRC-AS [78.6% (OR: 6.7, NS), 83.3% (OR: 13.3, P<.005), and 81.8% (OR: 12.2, P<.005), respectively], without significant variations among CRC stages. These findings collectively suggest that CRC patients predominantly exhibit C-carrier status with homozygous genotype, irrespective of CRC stage, and underscore a strong association with CRC-associated VTE.

Given the high prevalence of the CDKN2B-AS1 C-allele and its association with hypercoagulability in CRC-AS patients, we explored genetic predispositions related to thromboembolic risk. A distinctive pattern emerged, particularly among C-carriers with CRC (Fig.1E). Notably, variants of FII-(A), FV-(Leiden), and

FGB-(A) were significantly more frequent in C-carriers compared to non-C-carriers [28.7% vs. 5.3% (P<.05); 44.3% vs. 15.8% (P<.01); 74.0% vs. 21.1% (P<.0001), respectively]. Conversely, FXIII-(Leu) exhibited markedly lower allele frequency in C-carriers (-70.9%, P<.0001) compared to non-C-carriers. Other genetic variants directly associated with thromboembolic risk (FV-(R2), PAI-1-(4G), MTHFR-(C/T, A/C), HPA1-(1b)), or indirectly

implicated in the vascular system and related pathways (ACE-(Del), ApoB-(R/Q), ApoE-(E2/E4)) showed no significant variants, whereas four polymorphisms (FV-(Cambridge), FV-(Y1702C), MTR-(2756), and MTRR-(66)) weren't detected. These findings suggest an elevated risk of thromboembolic events in CRC patients who are C-carriers.

3.4. Circulating Immune Cells (CICs) Profile in CRC C-carriers

The investigation of Circulating Immune Cells (CICs) in CRC patients carrying the CDKN2B-AS1-Callele underscores their pivotal role in immune dysregulation and inflammation during CRC carcinogenesis. Understanding their dynamics in relation to C-allele offers valuable insights into potential biomarkers and pathways influencing CRC development and prognosis.

Initially, a comprehensive assessment including Complete Blood Count (CBC), differential, and Peripheral Blood Mononuclear Cells (PBMCs) was conducted (Fig. 2A). Significant variations were observed, particularly correlating with CRC staging, with the most pronounced changes seen in the CRC-AS group. Within CRC-AS, notable increases were noted in total PBMCs, monocytes, and neutrophils [1.95, 2.94, and 2.89-fold increase respectively], alongside a substantial decrease in lymphocyte count (-57.0%). The Neutrophil-to-Lymphocyte Ratio (NLR), indicative of inflammation, increased significantly (4.95-fold) compared to the control. Notably, different patterns may be exhibited within lymphocyte subsets, including cytotoxic, regulatory, and helper cells, warranting careful consideration.

Next, circulating PBMCs underwent immunophenotyping (Fig. 2B). Compared to the control, significant increases were observed in cells expressing $CD3^+$ (2.03-fold), $CD14^+$ (5.83-fold), $CD31^+$ (5.44-fold), $CD34^+$ (2.01-fold), $CD105^+$ (2.54-fold), $CD144^+$ (4.31-fold), and $VEGFR2^+$ (6.08-fold) within the CRC groups, with CRC-AS exhibiting the highest counts. Conversely, a significant decrease of -74.4% was noted in $CD146^+$ cells. No significant variations were observed in the counts of $CD29^+$, $CD45^+$, $CD73^+$, $CD90^+$, and $CD133^+$ cells. Additionally, although decreases in the number of cells expressing HLAABC/DR (MHC) antigens were observed in CRC groups, these decreases did not reach statistical significance. Viability and apoptotic index, assessed using Annexin V/PI/7AAD, showed no significant changes with CRC staging (Fig. 2C). The data revealed predominant increases in the abundance of two hematopoietic progenitor cells, $CD14^+$ monocytes, and VEGFR-2^+, primarily involved in angiogenesis, in advanced CRC stages. Elevated $CD144^+$ expression suggests potential involvement in cancer progression, indicating acquisition of angiogenic potential by PBMCs. Significant increases were also observed in $CD31^+$ cells, which are known for their role in platelet activation and may increase thrombotic risk through the formation of monocyte-platelet aggregates. Conversely, the decrease in $CD146^+$ cells, known for their tumor-suppressive roles (in suppressing tumorigenesis, cancer stemness, and Th17 cells), may promote tumor progression as suppression diminishes with CRC advancement. These findings collectively support the hypothesis that these alterations may contribute to cancer cells evading the immune system and

enhancing their metastatic potential.



C

Cell Type (%)	Control (n=229)	CRC-ES (n=68)	CRC-MS (n=77)	CRC-AS (n=74)
Annexin V^- PI^- $7AAD^-$	97.6 ± 1.1	98.9 ± 1.3	94.1 ± 2.0	91.5 ± 2.4
Annexin V^+ PI^- $7AAD^-$	2.0 ± 0.8	1.0 ± 1.2	3.6 ± 1.2	3.6 ± 1.9
Annexin V^+ PI^+ $7AAD^+$	0.4 ± 0.7	0.1 ± 0.5	2.3 ± 1.7	4.9 ± 1.2

<u>Fig.2 Legend</u>: Frequencies and Immunophenotyping of Circulating Immune Cells (CICs) in CDKN2B-AS1 C-carriers with

CRC. *hPBMCs were isolated from CDKN2B-AS1 C-carriers as detailed in the methods. (A) Frequencies of CICs within PBMCs: Counts are expressed as absolute values of fresh cells and presented as a percentage variation relative to controls [counts in controls were as follows: PBMC (1.11), WBC (7.80), Platelets (269.4), Monocytes (0.72), Neutrophils (6.3), Lymphocytes (2.82) x10^3/µL, and NLR (ratio: 3.02)]. Flow cytometry was employed for the assessment of (B) immunophenotyping and (C) cell viability and apoptotic index of CICs. A total of 2x10^5 cells were stained with fluorescence-conjugated antibodies targeting specific markers: CD3 (T-cells); CD14 (monocytes); CD29 (MSCs); CD31 (endothelial cells, megakaryocytes, and platelets);*

CD34 (hematopoietic stem cells); CD45 (all leukocytes); CD73 (MSCs marker); CD90 (Thy-1 thymus cell antigen, also an

MSCs marker); CD105 (endoglin, a regulatory component of the TGF-beta receptor-cell complex, also an MSCs marker); CD133 (a cancer stem cell marker in CRC); CD144 (VE cadherin); CD146 (a marker of tumor progression and metastatic formation in melanoma, suppressor of tumorigenesis and cancer stemness in CRC, and suppressor of Th17 cells); CD309

(VEGFR-2); Annexin V, PI, and 7AAD. Cells were categorized as viable (Annexin V^- PI^- $7AAD^-$), early-apoptotic (Annexin V^+ PI^- $7AAD^-$), and late-apoptotic/necrotic (Annexin V^+PI^+ $7AAD^+$). Results are expressed as mean±SEM in percentage of total cells expressing the studied markers and reported as percentage variation relative to the control. Experiments were conducted in duplicate. PBMC, peripheral blood mononuclear cells; WBC, white blood cells; NLR, neutrophil-to-lymphocyte ratio; MSCs,

*mesenchymal stem cells; PI, propidium iodide. *P<.01, **P<.001; CRCs versus Control.*

Different subclasses of circulating $CD3^+$ T-cells, including $CD3^+CD4^+$ (helper T-cells), $CD3^+CD8^+$

(cytotoxic T-cells), $CD3^+CD25^+$ (regulatory T-cells), and $CD3^+CD38^+$ (activated T-cell subset), as well as $CD3^-CD56^+$ (NK cells) were investigated, to explore their potential prognostic significance in CRC, specifically in relation to the CDKN2B-AS1 C allele (Fig.3). Marked variations were evident in C-carrier CRC-AS patients; notably, significant elevations were observed in $CD4^+$, $CD25^+$, and $CD38^+$ (6.45, 2.44, and 2.36-fold, respectively) relative to controls. Conversely, significant reductions were noted in $CD8^+$ T-cells (-75.4%) and $CD3^-$ $CD56^+$ NK cells (70.0%). The CD4:CD8 ratio significantly increased to a 24.2-fold, while the CD8:CD25 ratio, recognized as a predictive marker for survival in CRC patients, decreased significantly (-86.1%) (Fig.3A). An increased CD4:CD8 ratio could suggest a chronic inflammation or immune dysregulation, potentially promoting tumor growth and progression, while a decreased CD8:CD25 ratio may indicate immunosuppression and immune evasion mechanisms favoring tumor progression. The overall impact of these systemic immune alterations on tumor progression depends on various factors, including the tumor microenvironment and the balance of pro-tumor and anti-tumor immune responses. Thus, further investigation is necessary to understand the precise implications for CRC progression and prognosis.

Notably, significant variances in T-helper cells, crucial components of the immune contexture linked to CRC prognosis in human CRC [38], were observed among circulating T-cells. Given their relevance to inflammation, strongly associated with CRC [39], we explored the potential link between these T-helper cells and CRC, particularly concerning the CDKN2B-AS1 risk C-allele. Inflammatory phenotypes (Th1/Th2/Th17) were evaluated, where Th1 and

Th17 cells are proinflammatory, while Th2 cells are antiinflammatory [40]. Our results (Fig.3B) revealed significant increases in Th1 (2.9-fold) and Th17 (20.1fold) cells in CRC, especially in CRC-AS C-carriers. Conversely, a significant decrease in Th2 cells was observed (-73.8%). The Th17:Th1 ratio increased significantly by 7.0-fold, and the Th17:Th2 ratio even more pronouncedly by 71.8-fold. Additionally, the Th1:Th2 ratio increased significantly by 10.3-fold. These findings underscore the critical role of Th-cells and provide evidence of an inflammatory status

linked to the presence of the risk C-allele, mediated by Th1 and Th17 cells.



***Fig.3 Legend*: Immunoprofile of Circulating T-cells in CRC Patients Carrying the CDKN2B-AS1 Risk Allele**. *PBMCs were isolated from CDKN2B-AS1 C-carriers and non-C-carriers as described in the methods. The cells were labelled with human conjugated antibodies against specific markers and analyzed by flow cytometry. (A)*

*Subpopulations of CD3+ T-cells including $CD4^+$(helper), $CD8^+$(cytotoxic), $CD25^+$(regulatory), and $CD38^+$(activated), as well as $CD56^+$(NK). (B) Th1, Th2, and Th17 immunoprofile. Cells were labelled with human conjugated antibodies CD4-PerCP-Cy5.5, IFN-γ-FITC, IL-4-APC and IL-17A-PE for Th1, Th2, and Th17 cells. Phenotypes were defined as $CD45^+CD4^+IFN\text{-}\gamma^+$ (Th1), $CD45^+CD4^+IL\text{-}4^+$ (Th2), and $CD45^+CD4^+IL\text{-}17A^+$ (Th17). The results are expressed as percentage of positive cells ±SEM, reported in fold change relative to control non-C-carriers, and the experiments were realized in triplicates. *P<.05, **P<.01 and ***P<.001; C-*

carrier versus non-C-carrier. Th1, Th2 and Th17

3.5. Inflammatory Biomarkers and Cytokine Levels in CRC C-carriers

Inflammation dysregulation impacts CRC-related biomarkers, including among others elevated serum LDH levels and the production of circulating cytokines. These factors are associated with poor clinical outcomes and therapy resistance, emphasizing the need for their assessment in CRC patients stratified by CDKN2B-AS1 C-carrier status (Fig.4).

Our investigation revealed significant increases in circulating inflammatory markers and inflammationassociated markers, such as CRP, CAR (CRP-to-Albumin ratio), NLR (Neutrophil-to-Lymphocyte ratio), PLR (Platelet-to-Lymphocyte ratio), LDH, ferritin, and fibrinogen (Fig. 4A). Interestingly, these elevations were more pronounced in advancing stages of C-carrier CRC patients, with fold changes of 18.8, 17.7, 11.6, 3.14, 6.79, 4.7, and 4.5, respectively. Additionally, we explored D-dimer levels, a hypercoagulabilityassociated inflammation marker known for its role in cancers. In CRC-AS C-carriers, D-dimer levels significantly increased by 12.6-fold. Furthermore, circulating calcium levels (also known as Factor IV), previously linked to CRC prognosis [41] and correlated with lower survival rates, have been studied.

Notably, our data revealed significantly elevated circulating calcium levels in C-carrier CRC patients: CRC-ES (2.9-fold), CRC-MS (6.6), and CRC-AS (8.7-fold increases).

The analysis of circulating cytokine profiles (Fig. 4B) revealed that the levels of pro-inflammatory cytokines (IL-17A > IL-6 > IL12p70 > TNF-α and IFN-γ > IL-2) were significantly elevated in CRC Ccarriers compared to non-C-carriers. These levels increased notably in advancing stages, reaching fold changes of 44.1, 8.84, 6.12, 4.16, 4.12, and 2.62, respectively. Conversely, anti-inflammatory cytokines IL-4 and IL-10 exhibited significant decreases (-86.9% and -63.0%, respectively), which may impede tissue repair and homeostasis, potentially contributing to inflammation-induced tumorigenesis. No significant variations were observed for INF-α, GM-CSF, IL-5, and IL-9. The dysregulated cytokine balance in CRC could play a crucial role in the inflammatory microenvironment associated with disease progression, with potential implications for targeted therapeutic approaches.



***Fig.4 Legend*: *Dysregulated Inflammatory Markers and Cytokines levels in CRC Patients Carrying the CDKN2B-AS1 Risk Allele*.** *(A) Serum levels of inflammatory markers were quantified, including CRP, CAR, NLR, PLR, LDH, and ESR, as well as other markers: Ferritin, Fibrinogen, D-Dimer, and Calcium. (B) Profile of cytokines in peripheral blood as analyzed. Undiluted samples were assessed as described in Methods. The limit*

*of detection (pg/ml) for cytokines were: IFN-γ (6.26), IFN-α (10.4), TNF-α (2.17), GM-CSF (0.20), IL-2 (1.52), IL-4 (34.2), IL-5 (0.27), IL-6 (0.077), IL-9 (32.7), IL-10 (2.76), IL-12 (3.44), and IL17A (0.7). The results are expressed as fold of variation relative to the non-C-carriers control group ±SEM, with measures conducted in duplicates. *P<.05, **P<.01 and ***P<.001; C-carrier versus non-C-carrier. Abbreviations: CRP, C-reactive protein; CAR, CRP-to-albumin ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LDH, lactate*

dehydrogenase; ESR, Erythrocyte Sedimentation Rate.

3.6. Circulating Endothelial Progenitor Cells (EPCs) and Angiogenesis in CRC C-carriers

EPCs, integral to neovascularization, have drawn interest in cancer biology, particularly their potential link to CRC. Their involvement in tumor angiogenesis suggests a role in tumor progression and metastasis, making them prospective biomarkers for disease detection and staging [42]. Neoplastic site vascularization is crucial for cancer survival and progression, with EPCs proliferating and differentiating into active endothelial cells, influencing vascular homeostasis and vasculogenesis. Notably, circulating EPC levels are elevated in CRC patients [43]. Therefore, we aimed to determine whether any variations occur in CRC patients, predisposed or not to the CDKN2-AS1 C-allele.

Distinctive phenotypes of EPC subpopulations were studied based on cells having features—circulating or tissue-adherent, including interactions with tumor sites. Given our focus on circulating cells, explored features critical for cell migration and recruitment to tissue injury sites, especially the tumor microenvironment. Based on specific markers (CD31, CD34, CD45, CD144, KDR (VEGFR2), and CXCR4), we identified two EPCs groups: Circulating Non-Tissue-Adherent EPCs (NTA-EPCs) and Tissue-Adherent EPCs (TA-EPCs).

Furthermore, we distinguished two subpopulations in TA-EPCs based on the expression of the CD146, an endothelial cell marker suppressor of tumorigenesis. In summary, our study identified three distinct EPC phenotypes within the CRC patient population (Table III).

Table III: Endothelial Progenitor Cells (EPCs) Phenotypes in CRC Patients

EPCs PHENOTYPES	Marker Expression [1]
Circulating Non-Tissue-Adherent EPCs (NTA-EPCs)	
Phenotype "A"	$CXCR4^{+}/KDR^{+}/CD31^{+}/CD34^{+}/CD45^{-}/CD144^{-}/CD146^{-}$
Circulating Tissue-Adherent EPCs (TA-EPCs)	
Phenotype "B", TA-EPCs lacking CD146	$CXCR4^{+}/KDR^{+}/CD31^{+}/CD34^{+}/CD144^{+}/CD45^{-}/CD146^{-}$
Phenotype "C", TA-EPCs expressing CD146	$CXCR4^{+}/KDR^{+}/CD31^{+}/CD34^{+}/CD144^{+}/CD146^{+}/CD45^{-}$

Table III Footnote: [1] ***CD31 (****PECAM-1), is commonly expressed in endothelial cells, particularly EPCs.* ***CD34,*** *is a marker associated with hematopoietic stem and progenitor cells, including EPCs.* ***CD45,*** *is a marker associated with hematopoietic cells, particularly leukocytes; EPCs are typically negative for CD45, indicating a non-hematopoietic lineage.* ***CD144 (****VEcadherin), is an endothelial-specific adhesion molecule critical for maintaining endothelial integrity and mediating cell-cell adhesion in endothelial junctions.* ***CD146 (****MCAM), is a marker associated with endothelial cells and pericytes, facilitating adhesion and interaction with the vasculature, while also being implicated in angiogenesis and recognized for its suppressor role in tumorigenesis.* ***KDR (****VEGFR2), is a receptor for VEGF and plays a pivotal role in angiogenesis, mediating the cellular responses to VEGF stimulation in endothelial cells, including EPCs.* ***CXCR4, i****s a chemokine receptor associated with migration and homing of cells toward chemokine gradients, which may guide EPCs to specific tissue locations, including tumor sites.*

As shown in Fig.5, CRC patients with the C-carrier genotype exhibited significantly elevated levels of circulating EPCs expressing both phenotype A and B. Specifically, a 3.73-fold increase for phenotype A was observed in CRC-AS, while phenotype B holds a substantial 7.1-fold increase in CRC-AS compared to the control group. Conversely, a marked reduction in the levels of circulating EPCs expressing phenotype C, characterized by TA-EPCs expressing CD146, reached highest decreases in CRC-AS (80.8%,P<0.001).



Fig.5 Legend: EPCs Surface Marker Analysis in CRC: Influence of CDKN2B-AS1 C-carrier Status on Phenotypic

Distribution. *PBMCs isolated from CDKN2B-AS1 C-carriers and non-C-carriers were analyzed for the distribution of EPCs' surface markers in CRC-ES/MS/AS groups and controls. Cells were labeled with human conjugated antibodies for CD31, CD34, CD45, CD133, CD144, CD146, VEGFR2 and CXCR4, and analyzed by flow cytometry. Three phenotypes were characterized as indicated in Table 5: Phenotype A represents NTA-EPCs lacking CD45, CD144, and CD146; Phenotype B denotes TA-EPCs lacking CD45 and CD146 but*

expressing CD144. Phenotype C signifies TA-EPCs lacking CD45 but co-expressing CD144 and CD146. Results are expressed as cells/µl ±SEM and represented as fold variation relative to the non-C-carriers control group (1.12±1.22, 0.41±0.90, 0.72±0.68, respectively for phenotype A, B, C). Experiments were realized in duplicate. Abbreviations:

EPCs, Endothelial Progenitor Cells; PBMCs, Peripheral Blood Mononuclear Cells; NTA-EPCs, circulating Non-Tissue-

*Adherent EPCs; TA-EPCs, Tissue-Adherent EPCs. *P<.05, **P<.01, ***P<.001; C-carrier versus non-C-carrier.*

3.7. Expression Profiles of Tumor-Infiltrating Immune Cells in CRC: Impact of CDKN2B-AS1 CAllele

Based upon our findings from circulating immune dynamics, we now shift our focus to the tumor microenvironment itself. Specifically, we investigate the expression profiles of specific tumor-infiltrating immune cell (TIIC) types in CRC patients, with a particular interest on the impact of the CDKN2B-AS1 C allele. Distinctive patterns associated with the risk C-allele were observed across various TIIC types, including $CD4^+$, $CD8^+$, $CD20^+$, $CD11c^+$, $CD56^+$, and $CD68^+$ cells (Fig.6A). Within the tumor microenvironment of C-carrier CRC-AS patients, we observed significantly elevated levels of infiltrated T-helper and notably Tregs cells (2.6 and 3.5-fold, respectively), which are associated with immunosuppressive functions, and a reduced levels of infiltrated cytotoxic, NK, and dendritic cells were detected (-63.5%, -52.0%, and -71.6%, respectively), which play crucial roles in anti-tumor immune responses. Interestingly, in advanced stages of C-carriers CRC, we observed a significant decrease in $CD68^+CD86^+$ M1-like macrophages (-58.4%) and a notable increase in $CD68^+CD163^+$ M2-like macrophages (4.2-fold), suggesting a shift towards a more immunosuppressive and tumor-promoting environment. Overall, these findings suggest a

tumor microenvironment characterized by immunosuppressive dynamics, potentially promoting tumor progression in CRC, especially in patients carrying the C-allele.

To comprehensively assess tumor characteristics, progression, and potential treatment responses, guiding the management and prognosis of C-carriers with CRC-AS, we examined key biomarkers commonly used for diagnostic, prognostic, or treatment purposes. These biomarkers included CEA, CA 19-9, CK-20, KRAS and BRAF mutations, EGFR, VEGF, immune checkpoint PD-1, CTLA-4, and the proliferation marker Ki-67. C-carriers demonstrated significantly elevated levels of several biomarkers, contrasting with MSI-H, which exhibited a significant decrease (Fig. 6B). CEA and CA 19-9, renowned tumor markers, showed significant increases of 5.22 and 2.60-fold, respectively. EGFR and VEGF-A, crucial markers in cancer progression and angiogenesis, presented increases of 2.29 and 4.66-fold, respectively. Remarkably, immune checkpoint markers PD-1 and CTLA-4 demonstrated substantial elevations of 13.3 and 9.16-fold, respectively, suggesting a potentially exhausted or suppressed immune response within the tumor microenvironment. Regarding specific gene mutations, the prevalence of BRAF mutation was higher in Ccarriers (6 out of 74 CRC-AS patients), showing a 6.01-fold increase compared to non-C-carriers (1 out of 74 CRC-AS patients), while KRAS mutation was undetected in both groups. Furthermore, MSI-H status, associated with genomic instability, was significantly lower in C-carriers, showing an -83.4% decrease.

Among the CRC-AS patients (n=74), the prevalence of MSI-H and BRAF mutation (termed here as BRAF+) was 9.46% each. Specifically, only 2.7% of patients had both MSI-H and BRAF V600E mutations. MSI-H occurred in 6 (8.11%) non-C-carriers and 1 (1.35%) C-

carrier out of 74 patients. In contrast, MSS was predominant, with 1 (1.35%) non-C-carrier and 66 (89.2%) C-carriers out of 74 CRCAS patients. BRAF mutations were present in 28.6% of MSI-H cases and 7.46% of MSS cases.

These findings collectively underscore the potential role of CDKN2B-AS1 C-allele in CRC progression and genetic predisposition. This was further supported by a significantly active tumor cell status (Fig.6C), as indicated by the proliferation marker Ki-67, which exhibited a notable 3.03-fold elevation in C-carriers. Additionally, there was an increase in CDK4/6 activity, evidenced by 2.95-fold, 2.71-fold, and 3.89-fold increases, respectively, in phospho-CDK4, phospho-CDK6, and phospho-Rb levels.

Given the data obtained, it is appropriate to classify individuals carrying the CDKN2B-AS1 C-allele as displaying an aggressive phenotype, termed the "**C-carrier aggressive phenotype**". This label aptly reflects the heightened presence of infiltrated T-helper and Tregs cells, reduced levels of cytotoxic, NK, and dendritic cells, as well as a significant shift from M1-to-M2 macrophage populations and increased expression of critical biomarkers associated with tumor progression and immune suppression. Additionally, the low MSI-H status observed suggests that tumors may evade immune surveillance more effectively, leading to a less favorable prognosis and potentially more aggressive behavior.



<u>Fig.6 Legend</u>: Characterization of Tumor Microenvironment and Biomarker Expression in CDKN2B-AS1 C-carrier CRCAS. *Tumor-Infiltrating Immune Cells (TIICs) and the expression of specific biomarkers were assessed in tumor biopsies or peripheral blood from CDKN2B-AS1 C-carriers and non-C-carriers. A,*

Expression of TIICs: Tumor biopsies were labelled with human conjugated antibodies for CD3, CD4, CD8, CD20, CD25, CD56, CD68, CD86, CD163, and CD11c, then analyzed by

IHC. Subpopulations of TIICs were identified as follows: T cells ($CD3^+$(total), $CD4^+$(helper), $CD8^+$(cytotoxic), $CD25^+$(regulatory)), $CD20^+$(B cells), $CD56^+$(NK), $CD68^+CD86^+$ (macrophages, M1 phenotype), $CD68^+CD163^+$ (macrophages, M2 phenotype), and $CD11c^+$ (dendritic). B, Molecular Profiling and Biomarker Evaluation: Tumor biopsies were labelled with human conjugated antibodies directed against CK-20, EGFR, VEGF-A, PD-1, and CTLA-4, then analyzed by IHC. The microsatellite instability (MSI) status was determined using IHC assessment of mismatch repair (MMR) proteins

(MLH1, MSH2, MSH6, and PMS2) on tumor biopsy samples, with MSI-H phenotype characterized by the loss of one or more MMR proteins' expression. KRAS and BRAF mutations were detected by PCR and reverse-hybridization, targeting specific codons (12 and 13 in Exon 2, 59 and 61 in Exon 3, and 117 and 146 in Exon 4) in the human KRAS gene, and codons (600 and

601) in the human BRAF gene. The levels of tumors markers CEA and CA 19-9 were evaluated in bloodstream (22.2 ng/ml and

46 U/ml in non-C-carriers, respectively). The results are expressed as percentage of variation relative to non-C-carrier. C,

*CDK4/6 and Proliferative Activities: Tumor biopsies were labelled with human conjugated antibodies directed against phosphoCDK4 (Thr172), phospho-CDK6 (Thr177), phospho-Rb (Ser807/811), and Ki67, then analyzed by IHC. Results are presented as H-Scores. *P<.05, **P<.01, ***P<.001; C-carrier versus non-C-carrier.*

3.8. Targeted Therapy in Focus: Palbociclib, a CDK4/6 Inhibitor

While chemotherapy remains a cornerstone of CRC treatment, its efficacy in individuals with the C-carrier aggressive phenotype may be suboptimal compared to those without the C-allele. To address this challenge, we adopted a combinatorial approach involving targeted therapy and chemotherapy, focusing on promising agents like Palbociclib (PAL), a CDK4/6 inhibitor known to target the CDK4/6 signaling pathways regulated by the lncRNA CDKN2B-AS1. In our study, CRC-AS patients received chemotherapy CAPOX, which combines capecitabine and oxaliplatin, either with or without Palbociclib. In our cohort of 74 CRCAS patients, 52 patients initially received chemotherapy CAPOX. However, some individuals left the study due to various reasons such as loss of contact, opting for treatment at other hospitals, declining second-line therapy, or leaving the country for socio-economic reasons. Additionally, post-baseline imaging was not conducted for 6 patients, rendering them not evaluable for analysis. As a result, our final analysis included 46 patients who received CAPOX, with 34 not receiving Palbociclib (PAL) treatment and 12 receiving PAL as second-line therapy. Adverse events (AEs) related to treatments were assessed, with additional, non-significant occurrences observed in patients who received CAPOX+PAL compared to those who received CAPOX alone. These included residual side effects, hypertension, headache, dry skin, back pain, and diarrhea.

The evaluation of treatment efficacy encompassed primary clinical endpoints such as Progression-Free Survival (PFS), along with secondary clinical endpoints like Tumor Regression (TRG) and the levels of previously investigated biomarkers (Fig.7). First, when

comparing PAL to the control treatment for the PFS, Kaplan-Meier curves exhibited significant differences associated with treatment (Log-rank=6.18, P=0.0012) (Fig.7A), indicating improvement. In fact, the median of PFS significantly increased from 9 months in control group to 20 months in PAL group. The PAL treatment response profiles differ significantly between C-carriers and non-C-carriers, with notable implications for therapeutic outcomes (Fig.7B). While neither group achieved a complete response (TRG0), the partial response was more pronounced in non-C-carriers, with 71.4% displaying this favorable outcome (TRG1) and only 14.3% having minimal or no response to treatment (TRG3). Conversely, a higher proportion of C-carriers exhibited poorer responses, with 33.3% showing partial response (TRG1) and 58.3% demonstrating minimal or no response to treatment (TRG3). These findings underscore the potential influence of genetic predisposition, specifically the lncRNA CDK2B-AS1, on treatment efficacy. The biomarker levels at 1year post PAL treatment demonstrate differential responses between groups. Relative to baseline, the levels of CEA, CA 19-9, EGFR, VEGF-A, PD-1, CTLA-4, and Ki-67 decreased in both CRC-AS groups, with more pronounced impact of PAL on reducing biomarker levels in non-C-carriers compared to C-carriers:

[53.2% (P<0.001), 43.5% (P<0.001), 10.1% (NS), 10.5% (NS), 30.4% (P<0.05), 21.4% (P<0.05), 73.4%

(P<0.0001), respectively in non-C-carriers; and 15.1% (NS), 10.1% (NS), 4.8% (NS), 8.9% (NS), 7.8% (NS), 12.0% (NS), 47.7% (P<.001), respectively in C-carriers). Overall, these findings shed light on the varying effects of PAL depending on the LncRNA genetic predisposition of CDKN2B-AS1, especially on tumor markers and immune checkpoint markers, coupled with a robust significant reduction in the cell proliferation marker Ki-67.

These insights are pivotal in tailoring treatment strategies, suggesting the need for personalized approaches based on genetic profiles to optimize therapeutic outcomes and improve patient prognosis.



<u>Fig.7 Legend</u>: Impact of Palbociclib Treatment on Progression-Free Survival and Treatment Response in C-carriers with CRC-AS. *A, Evaluation of progression-free survival (PFS) in C-carriers CRC-AS patients who received Palbociclib (PAL) treatment post-CAPOX chemotherapy (PAL group, n = 12) and those did not receive PAL (control group (-), n = 34). PFS was monitored over a 12-month period following treatment completion, with any instances of tumor progression during this period contributing to the PFS endpoint. Kaplan-Meier curves illustrate PFS outcomes, and median PFS (mPFS). B, Tumor regression grade (TRG) post-PAL treatment at 12-months post-therapy was assessed in both C-carriers and non-C-carriers using the AJCC TRG system. Patients categorized as TRG0 and TRG1 exhibited favorable treatment responses, while those classified as TRG2 and TRG3 showed poorer responses. Biomarker expression levels are shown relative to baseline in both C-carriers and non-Ccarriers. *P<.05, **P<.01, ***P<.001; Post-treatment versus Baseline.*

4. Discussion

This study identifies the LncRNA CDKN2B-AS1 C-variant as a "pan-cancer risk biomarker with prevalent occurrence", revealing its ubiquitous presence across various cancer types and its role as a significant risk indicator, particularly solid carcinomas. Its highest occurrence is noted in gastrointestinal cancers, followed by lung, genitourinary, breast cancer, and others. Moreover, it enhances susceptibility to colorectal cancer (CRC), with the most significant effects observed in patients at advanced stages (CRC-AS). A notable decrease in overall survival and an increased incidence of thromboembolic events were observed, concomitantly with higher frequencies of thromboembolic-associated polymorphisms such as FGB (A), FV (Leiden), and FII (A), and decreased frequency of the protective FXIII (V34L). CRC-AS C-carriers exhibited an immunosuppressive phenotype characterized by a proinflammatory state and impaired immunosurveillance in both circulating immune cells (CICs) and tumor-infiltrating immune cells (TIICs), alongside an increase in angiogenic endothelial progenitor cells (EPCs), potentially contributing to CRC progression and angiogenesis. Significant increases were noted in circulating peripheral blood cells, including PBMCs, monocytes, and neutrophils, accompanied by a decrease in lymphocyte levels. Among PBMCs, there was a notable rise in VEGFR-2, $CD14^+$, $CD31^+$, $CD144^+$, $CD105^+$, and $CD34^+$, while tumor suppressor-$CD146^+$ cells showed a significant decrease. Shifts in T-cell populations were observed in the CICs, with increases in $CD4^+$, $CD25^+$, and $CD38^+$ subsets, along with decreases in circulating $CD8^+$ T-cells and $CD3^-CD56^+$ NK cells. Notably, there were increases in Th1 and Th17 subsets, while Th2 saw a drastic decrease. Elevated levels of inflammatory and coagulation markers, as well as proinflammatory cytokines, were observed, contrasting

with decreased anti-inflammatory cytokines. Interestingly, circulating EPCs were markedly affected, with levels of non-tissue-adherent EPCs (NTA-EPCs) and tissue-adherent EPCs (TA-EPCs) lacking CD146 found to be higher, while TA-EPCs expressing CD146 were attenuated. Furthermore, TIICs showed a shift in T-regulatory cells and T-helper cells, with a reduction observed in dendritic, cytotoxic, and NK cells. Additionally, the expression of key CRC-associated biomarkers, including PD-1, CTLA-4, CEA, CA 19-9, EGFR, VEGF-A, and Ki-67, exhibited an increase. A higher prevalence of BRAF mutations and microsatellite stability (MSS) was observed in CRC-AS C-carriers, with no detected KRAS mutations, indicating an aggressive phenotype. Targeted therapy utilizing the CDK4/6 inhibitor Palbociclib (PAL) demonstrated a more favorable response in CRC-AS non-C-carriers compared to C-carriers, as evidenced by tumor regression and changes in cancer, angiogenic, and immune checkpoint biomarkers, highlighting the aggressive nature of the CRC C-carrier phenotype. Notably, progression-free survival (PFS) increased from 9 to 20 months following PAL treatment at the 1-year outcome.

Globally, the occurrence of the CDKN2B-AS1 C-variant varies among populations, typically around 0.42. Our findings are consistent with the published data, as we observed a frequency of 0.55 in the total population of 882 screened subjects, including both cancer-free individuals and those with cancer.

As well as ,ANRIL rs1333049 (G > C) and miR-146A rs2910164 (C > G) have been shown in studies to be useful indicators for predicting a better prognosis for patients with lung cancer undergoing platinumbased treatment [44]. Additionally, ANRIL elevated levels have been linked to lower survival rate and a higher metastatic rate in CRC patients [10]. Our

study provides insights into the prevalence of the C-allele across various cancer types, highlighting its greater involvement in solid tumors compared to hematological malignancies, with the highest levels observed in gastrointestinal cancers, particularly CRC. Seifi et al. reported that carriers of the CDKN2B-AS1 "C" risk allele had a higher risk of developing breast cancer [9,45]. Additionally, ANRIL rs1333049 (C>G) was found to be significantly associated with an increased risk of cancer, suggesting its potential as a new predictive marker for cervical carcinogenesis [46]. rs7017386 (C>G) was previously associated with CRC risk [47]. Furthermore, ANRIL rs1333049 and miR146A rs2910164 (C>G) have been identified as useful indicators for predicting a better prognosis in lung cancer patients undergoing platinum-based treatment [44]. Elevated levels of ANRIL have also been linked to lower survival rates and higher metastatic rates in CRC patients [10]. In fact, elevated levels of ANRIL, have been associated with increased CDK4/6 activity. ANRIL is involved in epigenetic regulation and can influence the expression of genes involved in cell cycle control, including CDK4 and CDK6. Therefore, increased levels of ANRIL can contribute to tumor progression by promoting CDK4/6 activity and enhancing tumor cell proliferation, thus ANRIL stands as a fascinating and multifaceted molecule with diverse implications in several types of cancer [14]. Interestingly, our C-carriers have high levels of CDK4/6 activity.

Increased incidence of VTE was noted in CRC-AS C-carriers. In fact, the role of CDKN2B-AS1 in thromboembolism is well established in a variety of diseases [18,48], most notably vascular diseases. The link between cancer and VTE has been well documented; in fact, cancer patients with abnormal blood clotting mechanisms are at significantly increased risk of thromboembolism, particularly those receiving systemic chemotherapy [49]. Our findings revealed elevated levels of D-dimer, fibrinogen, and shortened aPTT in agreement with

increased thromboembolic events, highlights the impact of the C-variant in CRC susceptibility. These thromboembolic dysregulations controlled by cancer cells including among others production of inflammatory and angiogenic cytokines, are confirmed in our cohort study [22,25,49].

ANRIL is thought to be involved in the formation of the tumor microenvironment matrix and may aid in cancer progression, so to be involved in tumor metastasis [9]. The tumor microenvironment is crucial in understanding immunosurveillance and immunoediting in cancer [20,21]. The connection between CDKN2B-AS1 and CICs in CRC showed strong involvement of inflammatory markers. Despite the decrease of total lymphocytes count in CRC groups, significant variations occurred in T-cells subsets. The CD8+ cytotoxic T-cells, key effectors of the cell-mediated immune response, are usually suppressed in cancers to promote tumor growth [50]; indeed, our results showed clearly a decreased CD8+ T-cells count in the C-carriers. CD4+ T-cells subsets in correlation with genetic predisposition showed a pronounced rise in the proinflammatory Th1 and Th17 contrary to a decrease in the anti-inflammatory Th2; high Th17 clusters have been previously linked to poor CRC prognosis [40]. Immune/inflammatory cells infiltrate practically all human solid tumors as they produce different cytokine subsets. Importantly, overproduction of Th17 cytokine product, IL-17A, marks the early stages of CRC and negatively influences the prognosis of CRC patients [51]. Evidences suggest that overproduction of IL-17A is associated with the production of VEGF and poor prognosis in patients with CRC [52]. The detected proinflammatory profile of circulating cytokines (high levels of IL17A, IL12p70, IL-6, IL-2,

TNF-α, and IFN-γ concomitantly with low levels of IL-4 and IL10) in CRC-AS C-carriers agree with the globally reported data.

Vascularization of neoplastic sites is a key characteristic that facilitates the survival and progression of cancer. EPCs undergo proliferation and differentiation into active endothelial cells, playing a vital role in vascular homeostasis and vasculogenesis [53]. In the context of cancer, this can have a dual effect. On the positive side, EPCs contribute to angiogenesis for tissue repair [54]. However, it's important to note that excessive or aberrant angiogenesis driven by EPCs can promote tumor growth and metastasis by enhancing new vessel formation, highlighting a potential negative aspect [43]. Furthermore, our study, consistent with previous findings, demonstrates elevated levels of circulating EPCs in CRC patients [43]. Interestingly, our study showed dynamics between circulating NTA-EPCs and TA-EPCs, especially with the impact in CRC of an aggressive phenotype expressing $CD146^{+}$. In fact, the significant decrease in CD146 expression in PBMCs, particularly in advanced CRC stages, is a noteworthy finding. CD146 has been associated with suppressing tumorigenesis and cancer progression, and its reduction in CRC patients may indeed suggest a loss of this suppression mechanism. Based on the EPCs phenotypes and the known roles of CD146 in tumor suppression and inhibiting cancer stemness, the increase in EPCs lacking CD146 (EPCs-$CD146^{-}$) may suggest a potential tumor-promoting role, where EPCs may lack the tumor-suppressive functions linked to CD146 expression and could potentially contribute to tumor progression or angiogenesis within the CRC microenvironment [55]. On the other hand, the decrease in EPCs expressing CD146 (EPCs$CD146^{+}$) implies also a potential loss of

the tumor-suppressive functions associated here with the absence of expression CD146 which could contribute to an environment more conducive to tumor growth and progression [56].

The dynamics of circulating EPCs in CRC-AS-C-carriers' patients exploring different phenotypes related to tissue-adherence features or not, gave more evidence of the potent role played by the circulatory system. However, no study has yet explored the role of CDKN2B-AS1 and its genetic variants on the dynamics of EPCs. In fact, the increases in cells expressing the CD144 (VE-cadherin), an endothelial-specific adhesion molecule critical for cell-cell adhesion in endothelial junctions, could indicate support for angiogenesis, thereby promoting tumor growth. One of the main inducers of EPCs mobilization is VEGF [57], highly released from CRC tumor tissues to recruit endothelial cells precursors [58]; hence proving a connection between chronic inflammation, CRC and EPCs. Our data showed higher levels of proinflammatory cells in advanced stages of CRC in C-carriers' patients with concomitant high levels of VEGF. Indeed, one could predict that the production and lifespan of EPCs could also depend on the individual genotype of CDKN2BAS1 gene.

The epigenetic profile of MSI plays a pivotal role in understanding CRC and significantly influences treatment decisions. Our findings indicate that CRC-AS patients carrying the C-allele are at a heightened [59]acknowledged that MSS tumors constitute 80-90% of CRC cases, whereas MSI-high (MSI-H) tumors occur in only 10-15%. The MSS phenotype has been consistently linked to poorer prognosis, increased mortality, and higher recurrence rates. Our data align with established standards of CRC treatment, which recommend chemotherapy for MSS patients and immunotherapy for those with the MSI phenotype. Our

model could have significant implications for tailoring treatment approaches to individual patients based on their genetic profiles.

In our studied cohort, despite the low prevalence of BRAF V600E ($BRAF^+$) mutation, with only 1.35% detected among non-C-carriers compared to 8.11% among C-carriers, a significant 6.00-fold increase was observed. Notably, the predominant phenotype observed among CRC-AS C-carriers with $BRAF^+$ mutations was MSS $BRAF^+$ (5 out of 66 patients, 7.58%). This finding is consistent with reported oncogenic mutations in the BRAF gene, particularly the V600E mutation, which accounts for approximately 10-12% of CRC cases [60]. Furthermore, it's recognized to be less common in CRC cases with MSS, estimated to occur in around 5-10% of MSS CRC cases.

The V600E mutation in the BRAF gene triggers constitutive activation of the BRAF protein within the MAPK pathway, leading to uncontrolled cell proliferation. This mutation drives aberrant MAPK signaling, fostering resistance to cell death, enhanced angiogenesis, EMT, and metastasis. Moreover, BRAF mutations, notably V600E, often confer resistance to anti-EGFR therapies. Our data reveal that CRC-ASC-carriers with the MSS phenotype exhibit elevated levels of Ki-67, EGFR, VEGF, PD-1, CTLA-4, CEA, and CA 19-9. This indicates an aggressive angiogenic phenotype with dysregulated MAPK-VEGF axis activity, impacting immune checkpoint regulation and circulating tumor markers. This underscores the complexity of CRC progression and highlights potential therapeutic targets.

The assessment of PAL, a CDK4/6 inhibitor, as second-line therapy following chemotherapy CAPOX (capecitabine and oxaliplatin) in CRC-AS patients revealed significant differences in PFS between PALtreated and control groups. Notably, the PAL group exhibited a median

increase in PFS from 9 to 20 months, accompanied by significant tumor regression. Moreover, when stratified by C-carrier status, PAL treatment response profiles indicated significant tumor regression and reductions in CRC-associated biomarkers that differed between C-carriers and non-C-carriers, highlighting the influence of genetic predisposition on therapeutic outcomes. Although tumor regression was observed from TRG3 (minimal response) to TRG1 (partial response) in both groups, the impact was more pronounced in non-C-carriers. These findings underscore the necessity for personalized treatment strategies based on genetic profiles to optimize therapeutic outcomes and improve patient prognosis.

As our results indicate, PAL primarily impacts cell proliferation, as evidenced by the notable decrease in Ki-67 levels. Additionally, there are moderate effects on immune checkpoints, as demonstrated by reductions in CTLA-4 and PD-1 levels. However, our observations indicate no significant impact on angiogenesis, as evidenced by the absence of notable changes in VEGF levels. Specifically, compared to baseline, a more pronounced reduction was observed in non-C-carriers compared to C-carriers.

The partial reversibility observed with Palbociclib suggests that individuals with the C-carrier aggressive phenotype may benefit from dual therapies targeting either (1) both the immune checkpoints and the tumor cell division cycle, or (2) both the VEGF axis and the tumor cell division cycle, rather than solely focusing on the latter. Both approaches hypothesize the use of immunotherapy combined with CDK4/6-targeted therapy. These strategies are supported by reported studies demonstrating the efficacy and challenges of targeting immune checkpoints [61] and angiogenesis [62–64] in CRC treatment. Moreover, kinase inhibitors could further enhance treatment outcomes. For example, Encorafenib, a small molecule BRAF inhibitor targeting the MAPK signaling pathway, has been utilized in combination

with the anti-EGFR cetuximab to treat CRC, particularly metastatic CRC with BRAF V600E mutation [65]. The interconnectedness of the MAPK pathway and CDKN2B-AS1 [66] with the CDK4/6 pathway suggests that complementary therapy targeting multiple pathways is essential for addressing the aggressive phenotype observed in CRC-AS C-carriers. A comprehensive therapeutic approach for CRC, especially the C-carrier aggressive phenotype, should target not only the proliferative axis but also angiogenic, immune checkpoint, and other implicated signaling pathways in disease progression.

It is well established that PAL inhibits CDK4/6, preventing the formation of cyclin D-CDK4/6 complexes that aid in Rb phosphorylation, thereby inhibiting cell cycle progression. In our model, where individuals carrying the risk C-allele of CDKN2B-AS1 exhibit elevated CDK4/6 activity, treatment with PAL resulted in marked inhibition of Ki-67. This suggests that the increased CDK4/6 activity associated with the Callele may contribute to enhanced tumor growth and proliferation. In fact, CDKN2B-AS1, an antisense transcript to the CDKN2B gene encoding p15INK4B, a cyclin-dependent kinase inhibitor that negatively regulates CDK4/6 activity, indirectly affects CDK4/6 activity and cell cycle progression by modulating CDKN2B expression. One potential scenario involves the C-allele of CDKN2B-AS1 decreasing p15INK4B expression, leading to elevated CDK4/6 activity, which promotes cell cycle progression and tumor growth. Alternatively, the C-allele of CDKN2B-AS1 may directly enhance CDK4/6 activity through other mechanisms, independent of p15INK4B regulation. Regardless of the scenario, elevated CDK4/6 activity in C-carriers underscores its pivotal role in carcinogenesis, making it a crucial target for therapy. Inhibiting CDK4/6 with Palbociclib reverses this effect, leading to suppression of cell proliferation and tumor regression.

5. Conclusion

In summary, this study investigates the impact of CDKN2B-AS1 polymorphism on various cancers, particularly CRC. It underscores the role of CDKN2B-AS1 in counteracting CDKN2B and its association with thromboembolism. Furthermore, it provides compelling evidence of significant alterations in CICs, EPCs, and TIICs subsets in CRC, influenced by the CDKN2B-AS1 polymorphism and microsatellite stability. Moreover, the study suggests a therapeutic approach to enhance CRC treatment by potentially inhibiting CDK4/6 using PAL as a promising target to mitigate immunosuppression and inflammatory reactivity in CRC. The inflammatory axis leading to tumor progression such as the MAPK-NF-kB or PI3kNF-kB pathways could give more comprehensive mechanistic insights of the LncRNA ANRIL and its risk C-allele in the development of cancer. The observed aggressive phenotype among C-carriers warrants further investigation, potentially suggesting the need for associated immunotherapy such as anti-angiogenic (anti-VEGF) treatment to overcome limitations in the therapeutic effectiveness of PAL. Thus, considering a combined therapy approach could yield improved outcomes. Our novel ongoing clinical trial evaluating the application of precision therapy combining PAL with Bevacizumab (an anti-VEGF agent) is currently active (NCT06307249). Additionally, given the absence of a direct RS1333049 inhibitor, exploring new types of therapies targeting the cell cycle in alternative ways is imperative.

Acknowledgments:

The authors would like to express their sincere gratitude to the medical director at Haykal Hospital, Dr. Lise Abi Rafeh, for her continuous support and guidance throughout the project. The authors also extend their appreciation to the laboratory supervisor, Mrs. Maya Al Eter,

for her invaluable assistance and expertise in overseeing the laboratory processes. Additionally, the authors would like to acknowledge the contributions of the lab technicians, Ms. Alaa Hamwi, the molecular biology technician, and Ms. Jenny Elia, the special chemistry technician, for their meticulous work and technical expertise that were instrumental to the success of this study.

Disclosures:

Funding Information

This study has been financed by the Lebanese University, Beirut-Lebanon, and Haykel Hospital, RasMaska-Lebanon.

Conflict of Interest

The authors, their families, their employers, and their business associates have no financial or proprietary interest in any product or company associated with any device, instrument, or drug mentioned in this study. The authors have not received any payment as reviewers, consultants, or evaluators of any of the instruments, devices, or drugs mentioned in this study.

Ethics Statement

All clinical investigations involving human samples were carried out in adherence to the principles outlined in the Declaration of Helsinki, as revised in 2008 (http://www.wma.net/e/policy/b3.htm), and it was registered in ClinicalTrials.gov (Identifier: NCT06065592). Written informed consent was obtained from all donors, and sample

collection was conducted in accordance with ethical guidelines. The study protocol received approval from the institutional review committee of Haykel Hospital (LUHH21/22/P04) renewed for 2023 (LUHH23/14/P06) and the scientific committee of the Lebanese University (1821/36/M, and 6341/4). These ethical approvals ensure that the study is conducted in a manner that respects the rights, welfare, and confidentiality of the participants. The internship to conduct this thesis in the field of molecular diagnostics has received the approval of Haykel Hospital for the period between February and September 2023, with the reference code ILUL220523_EMS which confirms the hospital's support and endorsement of the internship and thesis during the specified timeframe, specifically in the area of molecular genetics and Immunology. Animal studies: N/A.

Author Contributions

Elisa Makdessi (EM): principal investigator, study concept and design, experimental assessment, data collection and analyses, writing and critical revision of the manuscript. elisa.makdessi@ul.edu.lb Samar El-Hamoui (SEH): co-principal investigator, molecular genetics assessment, data collecting, technical measurement, analysis and interpretation of data, critical revision of the manuscript.

simcima@ymail.com

Fida El-Ayoubi (FEA): co-principal investigator, study concept and design, analysis of data.

fida.elmirelayoubi@ul.edu.lb

Malak Naboulsi (MN): co-principal investigator, medical laboratory analyses, data collection.

malak.naboulsi@gmail.com

David Wehbe (DW): co-principal investigator, hemato-oncologist, patients' enrollment, therapeutic application. wehbehdavid@hotmail.com

Noha Ibrahim (NI): co-principal investigator, molecular biology assessment. noha.ibrahim@ul.edu.lb

Nadine Nasreddine (NN): co-principal investigator, immunobiology assessment. nadineelghotmi@gmail.com

Nehman Makdissy (NM): Principal Investigator, study concept and design, experimental design, data collection, analyses and interpretation, statistical analysis, writing and critical revision of the manuscript.

nehman.makdissy@ul.edu.lb

References

[1] M. Huarte, The emerging role of lncRNAs in cancer, Nat Med 21 (2015) 1253–1261.

https://doi.org/10.1038/nm.3981.

[2] C.P. Ponting, P.L. Oliver, W. Reik, Evolution and functions of long noncoding RNAs, Cell 136 (2009)

629–641. https://doi.org/10.1016/j.cell.2009.02.006.

[3] T.R. Mercer, M.E. Dinger, J.S. Mattick, Long non-coding RNAs: insights into functions, Nat Rev

Genet 10 (2009) 155–159. https://doi.org/10.1038/nrg2521.

[4] A. Bhan, M. Soleimani, S.S. Mandal, Long Noncoding RNA and Cancer: A New Paradigm, Cancer

Res 77 (2017) 3965–3981. https://doi.org/10.1158/0008-5472.CAN-16-2634.

[5] S. Ne, INK4a/ARF: a multifunctional tumor suppressor locus, Mutation Research 576

(2005). https://doi.org/10.1016/j.mrfmmm.2004.08.021.

[6] W.Y. Kim, N.E. Sharpless, The regulation of INK4/ARF in cancer and aging, Cell 127 (2006) 265–

275. https://doi.org/10.1016/j.cell.2006.10.003.

[7] M.S. Cunnington, M. Santibanez Koref, B.M. Mayosi, J. Burn, B. Keavney, Chromosome 9p21 SNPs

Associated with Multiple Disease Phenotypes Correlate with ANRIL Expression, PLoS

Genet 6 (2010) e1000899. https://doi.org/10.1371/journal.pgen.1000899.

[8] L.M. Holdt, K. Sass, G. Gäbel, H. Bergert, J. Thiery, D. Teupser, Expression of Chr9p21

genes CDKN2B (p15(INK4b)), CDKN2A (p16(INK4a), p14(ARF)) and MTAP in

human atherosclerotic plaque, Atherosclerosis 214 (2011) 264–270.

https://doi.org/10.1016/j.atherosclerosis.2010.06.029.

[9] Y. Kong, C.-H. Hsieh, L.C. Alonso, ANRIL: A lncRNA at the CDKN2A/B Locus With Roles in Cancer and Metabolic Disease, Front Endocrinol (Lausanne) 9 (2018) 405. https://doi.org/10.3389/fendo.2018.00405.

[10] Y. Sun, Z.-P. Zheng, H. Li, H.-Q. Zhang, F.-Q. Ma, ANRIL is associated with the survival rate of patients with colorectal cancer, and affects cell migration and invasion in vitro, Molecular Medicine Reports 14 (2016) 1714–1720. https://doi.org/10.3892/mmr.2016.5409.

[11] Z. Sun, C. Ou, W. Ren, X. Xie, X. Li, G. Li, Downregulation of long non-coding RNA ANRIL suppresses lymphangiogenesis and lymphatic metastasis in colorectal cancer, Oncotarget 7 (2016)

47536–47555. https://doi.org/10.18632/oncotarget.9868.

[12] M.-L. Ma, H.-Y. Zhang, S.-Y. Zhang, X.-L. Yi, LncRNA CDKN2B□AS1 sponges miR□28□5p to regulate proliferation and inhibit apoptosis in colorectal cancer, Oncol Rep 46 (2021) 213.

https://doi.org/10.3892/or.2021.8164.

[13] P.J. Law, M. Timofeeva, C. Fernandez-Rozadilla, P. Broderick, J. Studd, J. Fernandez-Tajes, S.

Farrington, V. Svinti, C. Palles, G. Orlando, A. Sud, A. Holroyd, S. Penegar, E. Theodoratou, P.

Vaughan-Shaw, H. Campbell, L. Zgaga, C. Hayward, A. Campbell, S. Harris, I.J. Deary, J. Starr, L.

Gatcombe, M. Pinna, S. Briggs, L. Martin, E. Jaeger, A. Sharma-Oates, J. East, S. Leedham, R. Arnold, E. Johnstone, H. Wang, D. Kerr, R. Kerr, T. Maughan, R. Kaplan, N. Al-Tassan, K. Palin, U.A. Hänninen, T. Cajuso, T. Tanskanen, J. Kondelin, E.

Kaasinen, A.-P. Sarin, J.G. Eriksson, H. Rissanen, P. Knekt, E. Pukkala, P. Jousilahti, V. Salomaa, S. Ripatti, A. Palotie, L. RenkonenSinisalo, A. Lepistö, J. Böhm, J.-P. Mecklin, D.D. Buchanan, A.-K. Win, J. Hopper, M.E. Jenkins,

N.M. Lindor, P.A. Newcomb, S. Gallinger, D. Duggan, G. Casey, P. Hoffmann, M.M. Nöthen, K.-H. Jöckel, D.F. Easton, P.D.P. Pharoah, J. Peto, F. Canzian, A. Swerdlow, R.A. Eeles, Z. Kote-Jarai, K. Muir, N. Pashayan, The PRACTICAL consortium, B.E. Henderson, C.A. Haiman, F.R. Schumacher,

A.A. Al Olama, S. Benlloch, S.I. Berndt, D.V. Conti, F. Wiklund, S. Chanock, S. Gapstur, V.L. Stevens, C.M. Tangen, J. Batra, J. Clements, H. Gronberg, J. Schleutker, D. Albanes, A. Wolk, C.

West, L. Mucci, G. Cancel-Tassin, S. Koutros, K.D. Sorensen, E.M. Grindedal, D.E. Neal, F.C. Hamdy, J.L. Donovan, R.C. Travis, R.J. Hamilton, S.A. Ingles, B.S. Rosenstein, Y.-J. Lu, G.G. Giles, A.S. Kibel, A. Vega, M. Kogevinas, K.L. Penney, J.Y. Park, J.L. Stanford, C. Cybulski, B.G. Nordestgaard, C. Maier, J. Kim, E.M. John, M.R. Teixeira, S.L. Neuhausen, K. De Ruyck, A. Razack, L.F. Newcomb, M. Gamulin, R. Kaneva, N. Usmani, F. Claessens, P.A. Townsend, M. GagoDominguez, M.J. Roobol, F. Menegaux, K.-T. Khaw, L. Cannon-Albright, H. Pandha, S.N.

Thibodeau, A. Harkin, K. Allan, J. McQueen, J. Paul, T. Iveson, M. Saunders, K. Butterbach, J.

Chang-Claude, M. Hoffmeister, H. Brenner, I. Kirac, P. Matošević, P. Hofer, S. Brezina, A. Gsur, J.P. Cheadle, L.A. Aaltonen, I. Tomlinson, R.S. Houlston, M.G. Dunlop, Association analyses identify 31 new risk loci for colorectal cancer susceptibility, Nat Commun 10 (2019) 2154.

https://doi.org/10.1038/s41467-019-09775-w.

[14] A. Sanchez, J. Lhuillier, G. Grosjean, L. Ayadi, S. Maenner, The Long Non-Coding RNA ANRIL in

Cancers, Cancers 15 (2023). https://doi.org/10.3390/cancers15164160.

[15] Y. Xia, Y. Liu, C. Yang, D.M. Simeone, T.-T. Sun, D.J. DeGraff, M. Tang, Y. Zhang, X.-R. Wu, Dominant role of CDKN2B/p15INK4B of 9p21.3 tumor suppressor hub in inhibition of cell-cycle and glycolysis, Nat Commun 12 (2021) 2047. https://doi.org/10.1038/s41467-021-22327-5.

[16] F. Rahmani, A. Avan, F. Amerizadeh, G.A. Ferns, S. Talebian, S. Shahidsales, The association of a genetic variant in CDKN2A/B gene and the risk of colorectal cancer, EXCLI J 19 (2020) 1316–1321. https://doi.org/10.17179/excli2020-2051.

[17] N. Ghobadi, M. Mehramiz, S. ShahidSales, A. Rezaei Borojerdi, K. Anvari, M. Khazaei, M. Rezayi,

M. Sadegh Khorrami, M. Joudi□Mashhad, H. Ramshini, S. Ahmadi□Simab, A. Moradi, S.M.

Hassanian, M. Ghayour□Mobarhan, M.T. Boroushaki, G.A. Ferns, A. Avan, A genetic variant in *CDKN2A/2B* locus was associated with poor prognosis in patients with esophageal squamous cell carcinoma, Journal Cellular Physiology 234 (2019) 5070–5076. https://doi.org/10.1002/jcp.27310.

[18] N. Kaur, J. Singh, S. Reddy, ANRIL rs1333049 C/G polymorphism and coronary artery disease in a North Indian population - Gender and age specific associations, Genet Mol Biol 43 (2020) e20190024. https://doi.org/10.1590/1678-4685-GMB-2019-0024.

[19] W. Ahmed, I.S. Ali, M. Riaz, A. Younas, A. Sadeque, A.K. Niazi, S.H. Niazi, S.H.B. Ali, M. Azam, R. Qamar, Association of ANRIL polymorphism (rs1333049:C>G) with

myocardial infarction and its pharmacogenomic role in hypercholesterolemia, Gene 515 (2013) 416–420.

https://doi.org/10.1016/j.gene.2012.12.044.

[20] S. AbdulAzeez, A.N. Al-Nafie, A. Al-Shehri, J.F. Borgio, E.V. Baranova, M.S. Al-Madan, R.A. AlAli, F. Al-Muhanna, A. Al-Ali, M. Al-Mansori, M.F. Ibrahim, F.W. Asselbergs, B. Keating, B.P.C. Koeleman, A.K. Al-Ali, Intronic Polymorphisms in the CDKN2B-AS1 Gene Are Strongly Associated with the Risk of Myocardial Infarction and Coronary Artery Disease in the Saudi Population, International Journal of Molecular Sciences 17 (2016) 395. https://doi.org/10.3390/ijms17030395.

[21] J. Yang, L. Gu, X. Guo, J. Huang, Z. Chen, G. Huang, Y. Kang, X. Zhang, J. Long, L. Su, LncRNA

ANRIL Expression and ANRIL Gene Polymorphisms Contribute to the Risk of Ischemic Stroke in
the Chinese Han Population, Cell Mol Neurobiol 38 (2018) 1253–1269.

https://doi.org/10.1007/s10571-018-0593-6.

[22] A. Congrains, K. Kamide, R. Oguro, O. Yasuda, K. Miyata, E. Yamamoto, T. Kawai, H. Kusunoki,

H. Yamamoto, Y. Takeya, K. Yamamoto, M. Onishi, K. Sugimoto, T. Katsuya, N. Awata, K. Ikebe, Y. Gondo, Y. Oike, M. Ohishi, H. Rakugi, Genetic variants at the 9p21 locus contribute to atherosclerosis through modulation of ANRIL and CDKN2A/B, Atherosclerosis 220 (2012) 449–455.

https://doi.org/10.1016/j.atherosclerosis.2011.11.017.

[23] A. Falanga, M. Marchetti, A. Vignoli, Coagulation and cancer: biological and clinical aspects, J

Thromb Haemost 11 (2013) 223–233. https://doi.org/10.1111/jth.12075.

[24] L.G. Lima, R.Q. Monteiro, Activation of blood coagulation in cancer: implications for tumour progression, Biosci Rep 33 (2013) e00064. https://doi.org/10.1042/BSR20130057.

[25] A.A. Khorana, Venous Thromboembolism and Prognosis in Cancer, Thromb Res 125 (2010) 490–

493. https://doi.org/10.1016/j.thromres.2009.12.023.

[26] A.A. Khorana, C.W. Francis, E. Culakova, G.H. Lyman, Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study, Cancer 104 (2005) 2822–2829. https://doi.org/10.1002/cncr.21496.

[27] H. Sadeghi Rad, J. Monkman, M.E. Warkiani, R. Ladwa, K. O'Byrne, N. Rezaei, A. Kulasinghe, Understanding the tumor microenvironment for effective immunotherapy, Medicinal Research Reviews 41 (2021) 1474–1498. https://doi.org/10.1002/med.21765.

[28] M. Schmitt, F.R. Greten, The inflammatory pathogenesis of colorectal cancer, Nat Rev Immunol 21

(2021) 653–667. https://doi.org/10.1038/s41577-021-00534-x.

[29] A. Mezheyeuski, P. Micke, A. Martín-Bernabé, M. Backman, I. Hrynchyk, K. Hammarström, S.

Ström, J. Ekström, P.-H. Edqvist, M. Sundström, F. Ponten, K. Leandersson, B. Glimelius, T. Sjöblom, The Immune Landscape of Colorectal Cancer, Cancers (Basel) 13 (2021) 5545. https://doi.org/10.3390/cancers13215545.

[30] S. Pernot, M. Terme, T. Voron, O. Colussi, E. Marcheteau, E. Tartour, J. Taieb, Colorectal cancer and immunity: What we know and perspectives, World J Gastroenterol 20 (2014) 3738–3750. https://doi.org/10.3748/wjg.v20.i14.3738.

[31] J. Galon, A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce-Pagès, M. Tosolini, M.

Camus, A. Berger, P. Wind, F. Zinzindohoué, P. Bruneval, P.-H. Cugnenc, Z. Trajanoski, W.-H.

Fridman, F. Pagès, Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome, Science 313 (2006) 1960–1964. https://doi.org/10.1126/science.1129139.

[32] S. Emambux, G. Tachon, A. Junca, D. Tougeron, Results and challenges of immune checkpoint inhibitors in colorectal cancer, Expert Opinion on Biological Therapy 18 (2018) 561–573. https://doi.org/10.1080/14712598.2018.1445222.

[33] M. Caraglia, P. Correale, R. Giannicola, N. Staropoli, C. Botta, P. Pastina, A. Nesci, N. Caporlingua, E. Francini, L. Ridolfi, E. Mini, G. Roviello, D. Ciliberto, R.M. Agostino, A. Strangio, D. Azzarello,

V. Nardone, A. Falzea, S. Cappabianca, M. Bocchetti, G. D'Arrigo, G. Tripepi, P. Tassone, R. Addeo,

A. Giordano, L. Pirtoli, G. Francini, P. Tagliaferri, GOLFIG Chemo-Immunotherapy in Metastatic

Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up, Front. Oncol. 9 (2019) 1102. https://doi.org/10.3389/fonc.2019.01102.

[34] J. Roelands, P.J.K. Kuppen, L. Vermeulen, C. Maccalli, J. Decock, E. Wang, F.M. Marincola, D.

Bedognetti, W. Hendrickx, Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications, Int J Mol Sci 18 (2017) 2229. https://doi.org/10.3390/ijms18102229.

[35] J. d'Arc AlBacha, M. Khoury, C. Mouawad, K. Haddad, S. Hamoui, A. Azar, Z. Fajloun, N. Makdissy, High Incidence of ACE/PAI-1 in Association to a Spectrum of Other Polymorphic Cardiovascular Genes Involving PBMCs Proinflammatory Cytokines in Hypertensive

Hypercholesterolemic Patients: Reversibility with a Combination of ACE Inhibitor and Statin, PLoS ONE 10 (2015) e0127266. https://doi.org/10.1371/journal.pone.0127266.

[36] N. Makdissy, K. Haddad, J.D. AlBacha, D. Chaker, B. Ismail, A. Azar, G. Oreibi, D. Ayoub, I. Achkar, D. Quilliot, Z. Fajloun, Essential role of ATP6AP2 enrichment in caveolae/lipid raft microdomains for the induction of neuronal differentiation of stem cells, Stem Cell Res Ther 9 (2018) 132. https://doi.org/10.1186/s13287-018-0862-9.

[37] D. Chaker, C. Mouawad, A. Azar, D. Quilliot, I. Achkar, Z. Fajloun, N. Makdissy, Inhibition of the

RhoGTPase Cdc42 by ML141 enhances hepatocyte differentiation from human adipose-derived mesenchymal stem cells via the Wnt5a/PI3K/miR-122 pathway: impact of the age of the donor, Stem Cell Res Ther 9 (2018) 167. https://doi.org/10.1186/s13287-018-0910-5.

[38] D. Krijgsman, N.L. de Vries, A. Skovbo, M.N. Andersen, M. Swets, E. Bastiaannet, A.L. Vahrmeijer,

C.J.H. van de Velde, M.H.M. Heemskerk, M. Hokland, P.J.K. Kuppen, Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile, Cancer Immunol Immunother 68 (2019) 1011–1024. https://doi.org/10.1007/s00262-01902343-7.

[39] M. Tosolini, A. Kirilovsky, B. Mlecnik, T. Fredriksen, S. Mauger, G. Bindea, A. Berger, P. Bruneval, W.-H. Fridman, F. Pagès, J. Galon, Clinical Impact of Different Classes of

Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer, Cancer Research 71 (2011) 1263–1271. https://doi.org/10.1158/0008-5472.CAN-10-2907.

[40] I. Raphael, S. Nalawade, T.N. Eagar, T.G. Forsthuber, T cell subsets and their signature cytokines in autoimmune and inflammatory diseases, Cytokine 74 (2015) 5–17. https://doi.org/10.1016/j.cyto.2014.09.011.

[41] M.N. Silveira, L. Pozzuto, M.C.S. Mendes, L.P. Da Cunha, F.O. Costa, L.T. Macedo, S.R. Brambilla, J.B.C. Carvalheira, Association of Albumin-Corrected Serum Calcium Levels with Colorectal Cancer Survival Outcomes, JCM 11 (2022) 2928. https://doi.org/10.3390/jcm11102928.

[42] Y.-Z. Ge, R. Wu, T.-Z. Lu, H. Xin, P. Yu, Y. Zhao, H. Liu, Z. Xu, L.-W. Xu, J.-W. Shen, X. Xu, L.H. Zhou, W.-C. Li, J.-G. Zhu, R.-P. Jia, Circulating endothelial progenitor cell: a promising biomarker in clinical oncology, Med Oncol 32 (2015) 332. https://doi.org/10.1007/s12032-014-0332-x.

[43] Y. Li, J. Liu, Z. Zhao, L. Wen, H. Li, J. Ren, H. Liu, Correlation between circulating endothelial progenitor cells and serum carcinoembryonic antigen level in colorectal cancer, ABBS 50 (2018) 307– 312. https://doi.org/10.1093/abbs/gmx147.

[44] Y.-X. Chen, J. Chen, J.-Y. Yin, H.-H. Zhou, B.-M. He, Z.-Q. Liu, Non-Coding RNA Polymorphisms (rs2910164 and rs1333049) Associated With Prognosis of Lung Cancer Under Platinum-Based Chemotherapy, Front Pharmacol 12 (2021) 709528. https://doi.org/10.3389/fphar.2021.709528.

[45] S. Seifi, F. Pouya, M. Rahmani, M. Mehramiz, A. Rastgar□Moghadam, M. Gharib, F. Rahmani, S. Shahidsales, S.M. Hassanian, M. Khazaei, P. Dadjoo, S.S. Parvin, Y. Yazdinezhad, S.M.R. Parizadeh,

G.A. Ferns, M. Fathi, A. Avan, Association of cyclin□dependent kinase inhibitor 2A/B with increased risk of developing breast cancer, Journal Cellular Physiology 235 (2020) 5141–5145.

https://doi.org/10.1002/jcp.29388.

[46] M. Atabati, R. Saber, P. Malakuti, G. Pourali, M. Heydari-Majd, P. Safavi, M. Dashti, A.R. Moghadam, F. Rahmani, M. Farazestanian, N. Behboodi, M. Mehramiz, M. Nassiri, M. RajabianNoghondar, R. Rahbarian, H. Ramshini, A. Jafarian, G. Ferns, A. Avan, M. Hasanzadeh, Association of a Genetic Variant in Chromosome 9p21 with Increased Riskof Developing Cervical Cancer, CCTR 19 (2023) 358–362. https://doi.org/10.2174/1573394719666230321153528.

[47] H. Wang, Y. Zhu, H. Chen, N. Yang, X. Wang, B. Li, P. Ying, H. He, Y. Cai, M. Zhang, S. Niu, Y. Li, Z. Lu, X. Peng, D. Zou, R. Zhong, J. Chang, M. Dai, J. Tian, X. Miao, Colorectal cancer risk variant rs7017386 modulates two oncogenic lncRNAs expression via ATF1-mediated long-range chromatin loop, Cancer Letters 518 (2021) 140–151. https://doi.org/10.1016/j.canlet.2021.07.021.

[48] L.M. Holdt, F. Beutner, M. Scholz, S. Gielen, G. Gäbel, H. Bergert, G. Schuler, J. Thiery, D. Teupser,

ANRIL expression is associated with atherosclerosis risk at chromosome 9p21, Arterioscler Thromb Vasc Biol 30 (2010) 620–627. https://doi.org/10.1161/ATVBAHA.109.196832.

[49] A.A. Khorana, C.W. Francis, E. Culakova, G.H. Lyman, Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study, Cancer 104 (2005) 2822–2829. https://doi.org/10.1002/cncr.21496.

[50] K.E. de Visser, A. Eichten, L.M. Coussens, Paradoxical roles of the immune system during cancer development, Nat Rev Cancer 6 (2006) 24–37. https://doi.org/10.1038/nrc1782.

[51] V. De Simone, F. Pallone, G. Monteleone, C. Stolfi, Role of T_H 17 cytokines in the control of colorectal cancer, OncoImmunology 2 (2013) e26617. https://doi.org/10.4161/onci.26617.

[52] J. Liu, Y. Duan, X. Cheng, X. Chen, W. Xie, H. Long, Z. Lin, B. Zhu, IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma, Biochemical and Biophysical Research Communications 407 (2011) 348–354.

https://doi.org/10.1016/j.bbrc.2011.03.021.

[53] A. Reale, A. Melaccio, A. Lamanuzzi, I. Saltarella, F. Dammacco, A. Vacca, R. Ria, Functional and

Biological Role of Endothelial Precursor Cells in Tumour Progression: A New Potential Therapeutic Target in Haematological Malignancies, Stem Cells Int 2016 (2016) 7954580.

https://doi.org/10.1155/2016/7954580.

[54] T. Asahara, T. Takahashi, H. Masuda, C. Kalka, D. Chen, H. Iwaguro, Y. Inai, M. Silver, J.M. Isner, VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells, EMBO J 18 (1999) 3964–3972. https://doi.org/10.1093/emboj/18.14.3964.

[55] D. Liu, L. Du, D. Chen, Z. Ye, H. Duan, T. Tu, J. Feng, Y. Yang, Q. Chen, X. Yan, Reduced CD146 expression promotes tumorigenesis and cancer stemness in colorectal cancer through activating Wnt/β-catenin signaling, Oncotarget 7 (2016) 40704. https://doi.org/10.18632/oncotarget.9930.

[56] G. Zabouo, A.-M. Imbert, J. Jacquemier, P. Finetti, T. Moreau, B. Esterni, D. Birnbaum, F. Bertucci, C. Chabannon, CD146 expression is associated with a poor prognosis in human breast tumors and with enhanced motility in breast cancer cell lines, Breast Cancer Research 11 (2009) R1.

https://doi.org/10.1186/bcr2215.

[57] A. Ratajska, E. Jankowska-Steifer, E. Czarnowska, R. Olkowski, G. Gula, J. Niderla-Bielińska, A.

Flaht-Zabost, A. Jasińska, Vasculogenesis and Its Cellular Therapeutic Applications, Cells Tissues Organs 203 (2017) 141–152. https://doi.org/10.1159/000448551.

[58] E. Gunsilius, J. Tschmelitsch, M. Eberwein, H. Schwelberger, G. Spizzo, C.M. Kähler, G. Stockhammer, A. Lang, A.L. Petzer, G. Gastl, In vivo Release of Vascular Endothelial Growth Factor from Colorectal Carcinomas, Oncology 62 (2002) 313–317. https://doi.org/10.1159/000065062.

[59] J. Liu, H. Xie, BRAF Non-V600 Mutations in Metastatic Colorectal Cancer, Cancers 15 (2023) 4604. https://doi.org/10.3390/cancers15184604.

[60] F. Petrelli, M. Ghidini, M. Cabiddu, E. Pezzica, D. Corti, L. Turati, A. Costanzo, A. Varricchio, A.

Ghidini, S. Barni, G. Tomasello, Microsatellite Instability and Survival in Stage II Colorectal Cancer:

A Systematic Review and Meta-analysis, Anticancer Res 39 (2019) 6431–6441.

https://doi.org/10.21873/anticanres.13857.

[61] S. Makaremi, Z. Asadzadeh, N. Hemmat, A. Baghbanzadeh, A. Sgambato, F. Ghorbaninezhad, H. Safarpour, A. Argentiero, O. Brunetti, R. Bernardini, N. Silvestris, B. Baradaran, Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects, Biomedicines 9 (2021) 1075. https://doi.org/10.3390/biomedicines9091075.

[62] H. Liang, Y. Zhong, S. Zhou, L. Peng, Knockdown of RAGE expression inhibits colorectal cancer cell invasion and suppresses angiogenesis in vitro and in vivo, Cancer Letters 313 (2011) 91–98.

https://doi.org/10.1016/j.canlet.2011.08.028.

[63] A. Hussain, A.K. Qazi, N. Mupparapu, S.K. Guru, A. Kumar, P.R. Sharma, S.K. Singh, P. Singh, M.J. Dar, S.B. Bharate, M.A. Zargar, Q.N. Ahmed, S. Bhushan, R.A. Vishwakarma, A. Hamid, Modulation of glycolysis and lipogenesis by novel PI3K selective molecule represses tumor angiogenesis and

decreases colorectal cancer growth, Cancer Lett 374 (2016) 250–260. https://doi.org/10.1016/j.canlet.2016.02.030.

[64] H. Ma, J.-S. Pan, L.-X. Jin, J. Wu, Y.-D. Ren, P. Chen, C. Xiao, J. Han, MicroRNA-17~92 inhibits colorectal cancer progression by targeting angiogenesis, Cancer Letters 376 (2016) 293–302. https://doi.org/10.1016/j.canlet.2016.04.011.

[65] Z.T. Al-Salama, Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E

Mutation, Drugs 81 (2021) 849–856. https://doi.org/10.1007/s40265-021-01501-5.

[66] J. Pan, M. Lin, Z. Xu, M. Xu, J. Zhang, Z. Weng, B. Lin, X. Lin, CDKN2B antisense RNA 1 suppresses tumor growth in human colorectal cancer by targeting MAPK inactivator dual-specificity phosphatase 1, Carcinogenesis 42 (2021) 1399–1409. https://doi.org/10.1093/carcin/bgab077.

Declaration of interests

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☐ The author is an Editorial Board Member/Editor-in-Chief/Associate Editor/Guest Editor for *[Journal name]* and was not involved in the editorial review or the decision to publish this article.

☐ The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Nehman Makdissy
Corresponding Author